<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery - Amaral, FCF - 2022 | Cochrane Library</title> <meta content="Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery - Amaral, FCF - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013683.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery - Amaral, FCF - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013683.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013683.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery" name="citation_title"/> <meta content="Fabio CF Amaral" name="citation_author"/> <meta content="dr.fcabral@gmail.com" name="citation_author_email"/> <meta content="Jose CC Baptista-Silva" name="citation_author"/> <meta content="Luis CU Nakano" name="citation_author"/> <meta content="Ronald LG Flumignan" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD013683.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/11/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013683.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013683.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013683.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticoagulants [therapeutic use]; *Bariatric Surgery [adverse effects, methods]; Hemorrhage [etiology]; Heparin [therapeutic use]; *Pulmonary Embolism [etiology, prevention &amp; control]; Randomized Controlled Trials as Topic; *Venous Thromboembolism [drug therapy, prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013683.pub2&amp;doi=10.1002/14651858.CD013683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="tlnpj831";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013683\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013683\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013683\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013683\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ms","hr","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013683.pub2",title:"Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery",firstPublishedDate:"Nov 22, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tlnpj831&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013683.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013683.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013683.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013683.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013683.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013683.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013683.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013683.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013683.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013683.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2346 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013683.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full#CD013683-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full#CD013683-sec-0120"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full#CD013683-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full#CD013683-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full#CD013683-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full#CD013683-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full#CD013683-sec-0043"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full#CD013683-sec-0114"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/appendices#CD013683-sec-0125"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/supinfo/CD013683StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/supinfo/CD013683StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/information#CD013683-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Fabio CF Amaral</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/information#CD013683-cr-0005">Jose CC Baptista-Silva</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/information#CD013683-cr-0006">Luis CU Nakano</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013683.pub2/information#CD013683-cr-0007">Ronald LG Flumignan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/information/en#CD013683-sec-0130">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 November 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013683.pub2">https://doi.org/10.1002/14651858.CD013683.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013683-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013683-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013683-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013683-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013683-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013683-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013683-abs-0001" lang="en"> <section id="CD013683-sec-0001"> <h3 class="title" id="CD013683-sec-0001">Background</h3> <p>Venous thromboembolism (VTE), which comprises deep vein thrombosis (DVT) and pulmonary embolism (PE), is the leading cause of preventable death in hospitalised people and the third most common cause of mortality in surgical patients. People undergoing bariatric surgery have the additional risk factor of being overweight. Although VTE prophylaxis in surgical patients is well established, the best way to prevent VTE in those undergoing bariatric surgery is less clear. </p> </section> <section id="CD013683-sec-0002"> <h3 class="title" id="CD013683-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of pharmacological interventions (alone or in combination) on venous thromboembolism and other health outcomes in people undergoing bariatric surgery compared to the same pharmacological intervention administered at a different dose or frequency, the same pharmacological intervention or started at a different time point, another pharmacological intervention, no intervention or placebo. </p> </section> <section id="CD013683-sec-0003"> <h3 class="title" id="CD013683-sec-0003">Search methods</h3> <p>We used standard, extensive Cochrane search methods. The latest search date was 1 November 2021. </p> </section> <section id="CD013683-sec-0004"> <h3 class="title" id="CD013683-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and quasi‐RCTs in males and females of any age undergoing bariatric surgery comparing pharmacological interventions for VTE (alone or in combination) with the same pharmacological intervention administered at a different dose or frequency, the same pharmacological intervention started at a different time point, a different pharmacological intervention, no treatment or placebo. </p> </section> <section id="CD013683-sec-0005"> <h3 class="title" id="CD013683-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our primary outcomes were 1. VTE and 2. major bleeding. Our secondary outcomes were 1. all‐cause mortality, 2. VTE‐related mortality, 3. PE, 4. DVT, 5. adverse effects and 6. quality of life. We used GRADE to assess certainty of evidence for each outcome. </p> </section> <section id="CD013683-sec-0006"> <h3 class="title" id="CD013683-sec-0006">Main results</h3> <p>We included seven RCTs with 1045 participants. Data for meta‐analysis were available from all participants. </p> <p>Four RCTs (597 participants) compared higher‐dose heparin to standard‐dose heparin: one of these studies (139 participants) used unfractionated heparin (UFH) and the other three (458 participants) used low‐molecular‐weight heparin (LMWH). One study compared heparin versus pentasaccharide (198 participants), and one study compared starting heparin before versus after bariatric surgery (100 participants). One study (150 participants) compared combined mechanical and pharmacological (enoxaparin) prophylaxis versus mechanical prophylaxis alone. The duration of the interventions ranged from seven to 15 days, and follow‐up ranged from 10 to 180 days. </p> <p><b>Higher‐dose heparin versus standard‐dose heparin</b> </p> <p>Compared to standard‐dose heparin, higher‐dose heparin may result in little or no difference in the risk of VTE (RR 0.55, 95% CI 0.05 to 5.99; 4 studies, 597 participants) or major bleeding (RR 1.19, 95% CI 0.48 to 2.96; I<sup>2</sup> = 8%; 4 studies, 597 participants; low‐certainty) in people undergoing bariatric surgery. The evidence on all‐cause mortality, VTE‐related mortality, PE, DVT and adverse events (thrombocytopenia) is uncertain (effect not estimable or very low‐certainty evidence). </p> <p><b>Heparin versus pentasaccharide</b> </p> <p>Heparin compared to a pentasaccharide after bariatric surgery may result in little or no difference in the risk of VTE (RR 0.83, 95% CI 0.19 to 3.61; 1 study, 175 participants) or DVT (RR 0.83, 95% CI 0.19 to 3.61; 1 study, 175 participants). The evidence on major bleeding, PE and mortality is uncertain (effect not estimable or very low‐certainty evidence). </p> <p><b>Heparin started before versus after the surgical procedure</b> </p> <p>Starting prophylaxis with heparin 12 hours before surgery versus after surgery may result in little or no difference in the risk of VTE (RR 0.11, 95% CI 0.01 to 2.01; 1 study, 100 participants) or DVT (RR 0.11, 95% CI 0.01 to 2.01; 1 study, 100 participants). The evidence on major bleeding, all‐cause mortality and VTE‐related mortality is uncertain (effect not estimable or very low‐certainty evidence). We were unable to assess the effect of this intervention on PE or adverse effects, as the study did not measure these outcomes. </p> <p><b>Combined mechanical and pharmacological prophylaxis versus mechanical prophylaxis alone</b> </p> <p>Combining mechanical and pharmacological prophylaxis (started 12 hours before surgery) may reduce VTE events in people undergoing bariatric surgery compared to mechanical prophylaxis alone (RR 0.05, 95% CI 0.00 to 0.89; number needed to treat for an additional beneficial outcome (NNTB) = 9; 1 study, 150 participants; low‐certainty). We were unable to assess the effect of this intervention on major bleeding or morality (effect not estimable), or on PE or adverse events (not measured). </p> <p>No studies measured quality of life.</p> </section> <section id="CD013683-sec-0007"> <h3 class="title" id="CD013683-sec-0007">Authors' conclusions</h3> <p>Higher‐dose heparin may make little or no difference to venous thromboembolism or major bleeding in people undergoing bariatric surgery when compared to standard‐dose heparin. </p> <p>Heparin may make little or no difference to venous thromboembolism in people undergoing bariatric surgery when compared to pentasaccharide. There are inadequate data to draw conclusions about the effects of heparin compared to pentasaccharide on major bleeding. </p> <p>Starting prophylaxis with heparin 12 hours before bariatric surgery may make little or no difference to venous thromboembolism in people undergoing bariatric surgery when compared to starting heparin after bariatric surgery. There are inadequate data to draw conclusions about the effects of heparin started before versus after surgery on major bleeding. </p> <p>Combining mechanical and pharmacological prophylaxis (started 12 hours before surgery) may reduce VTE events in people undergoing bariatric surgery when compared to mechanical prophylaxis alone. No data are available relating to major bleeding. </p> <p>The certainty of the evidence is limited by small sample sizes, few or no events, and risk of bias concerns. Future trials must be sufficiently large to enable analysis of relevant clinical outcomes, and should standardise the time of treatment and follow‐up. They should also address the effect of direct oral anticoagulants and antiplatelets, preferably grouping them according to the type of intervention. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013683-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013683-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013683-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013683-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013683-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013683-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013683-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013683-abs-0013">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013683-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013683-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013683-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013683-abs-0002" lang="en"> <h3>Can medicines prevent venous thromboembolism after weight‐loss surgery?</h3> <p><b>What is venous thromboembolism?</b> </p> <p>Venous thromboembolism (VTE) is a clinical condition that usually starts when a blood clot forms inside a vein. The condition includes both deep vein thrombosis (when the clot forms in a deep vein, usually in the legs) and pulmonary embolism (when the clot forms in or reaches a blood vessel in the lungs). Both situations can substantially reduce quality of life and can be life‐threatening. People with obesity or who undergo surgery are more likely to experience VTE. Therefore, people undergoing a bariatric surgical procedure (aimed at reducing bodyweight by restricting food intake or absorption) are at particularly high risk. However, it is unclear whether these people should receive the same intervention to prevent VTE as people with other clinical conditions. </p> <p><b>How can venous thromboembolism be prevented?</b> </p> <p>VTE prophylaxis (preventive interventions) can be mechanical (e.g. elastic stockings or external compressive devices) or pharmacological (involving medicines that reduce blood clot formation, such as heparins, pentasaccharides or antiplatelet agents), or can combine both approaches. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to assess whether any pharmacological intervention can prevent VTE in people undergoing bariatric surgery, and whether these interventions are safe. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that examined the effect of any medicine for preventing VTE in people undergoing bariatric surgery, compared with the same medicine at a different dose, or given more or less often, or started at a different time point; or compared with a different medicine; or compared with no treatment or placebo (dummy treatment). We also included combinations of interventions. </p> <p>We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and size. </p> <p><b>What did we find</b> </p> <p>We found seven studies involving 1045 people who underwent bariatric surgery. The studies provided information about four different comparisons: </p> <p>1) heparin at a higher dose versus the same heparin at a standard dose; <br/>2) heparin versus a pentasaccharide; <br/>3) heparin started before versus after the surgical procedure; and<br/>4) combined mechanical and pharmacological prophylaxis versus mechanical prophylaxis alone.  </p> <p>Four studies provided information for the first comparison: one assessed unfractionated heparin (which is given by a medical professional and wears off quickly) and three assessed low‐molecular‐weight heparin (which patients can inject themselves and which lasts longer). There was one study for each of the other three comparisons. </p> <p>Heparin at a higher dose compared to a standard dose may make little or no difference to the risk of VTE or major bleeding in people undergoing bariatric surgery. The evidence on death, pulmonary embolism, deep vein thrombosis and the side effect thrombocytopenia (low blood platelet count) is uncertain. </p> <p>Heparin compared with pentasaccharide may make little or no difference to the risk of VTE or deep vein thrombosis in people undergoing bariatric surgery. The evidence on major bleeding, death, pulmonary embolism and side effects (thrombocytopenia, irregular heartbeat, rash and nausea and vomiting) is uncertain. </p> <p>Heparin before compared with after surgery may make little or no difference to the risk of VTE or deep vein thrombosis in people undergoing bariatric surgery. The evidence on major bleeding and death is uncertain. The study did not measure pulmonary embolism or harmful side effects. </p> <p>Mechanical prophylaxis plus pharmacological prophylaxis compared to mechanical prophylaxis alone may decrease the risk of VTE and deep vein thrombosis in people undergoing bariatric surgery. The evidence on major bleeding and death is uncertain. The study did not measure pulmonary embolism or harmful side effects. </p> <p>No studies measured the effect of any intervention on quality of life.</p> <p><b>Conclusion</b> </p> <p>Although there is some evidence on the effects of heparins, pentasaccharides and mechanical combined with pharmacological prophylaxis for preventing VTE in people undergoing bariatric surgery, we are still not sure which intervention works best. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We have little or very little confidence in the evidence because the studies were of low quality. Many participants dropped out from one study, there were a low number of events overall, and most studies had few participants. Larger studies assessing important outcomes (e.g. VTE, major bleeding, death due to any cause, death due to VTE, pulmonary embolism, deep vein thrombosis, harmful side effects and quality of life) are needed to assess which medicines are more effective and safer and at which dose they should be used. </p> <p><b>How up to date is this evidence?</b> </p> <p>This evidence is up‐to‐date to November 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013683-sec-0120" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013683-sec-0120"></div> <h3 class="title" id="CD013683-sec-0121">Implications for practice</h3> <section id="CD013683-sec-0121"> <p>In people undergoing bariatric surgery, higher‐dose heparin may result in little or no difference in venous thromboembolism (VTE) and major bleeding at 10 to 90 days of follow‐up. The evidence on the effect of higher‐dose heparin compared to standard‐dose heparin on all‐cause mortality, VTE‐related mortality, pulmonary embolism (PE), deep vein thrombosis (DVT) and adverse events (thrombocytopenia) is uncertain (effect not estimable or very low‐certainty evidence). </p> <p>Heparin compared with a pentasaccharide after bariatric surgery may result in little or no difference in the risk of VTE or DVT. The evidence on the effect of heparin compared to pentasaccharide on the other outcomes is uncertain (effect not estimable or very low‐certainty evidence). </p> <p>Starting prophylaxis with heparin 12 hours before bariatric surgery compared with starting heparin after bariatric surgery may result in little or no difference in the risk of VTE or DVT. The evidence on the effect of this intervention on major bleeding, all‐cause mortality and VTE‐related mortality is uncertain (effect not estimable or very low‐certainty evidence). We were unable to assess the effect of this intervention on PE and adverse events. </p> <p>Mechanical combined with pharmacological prophylaxis, compared to mechanical prophylaxis alone, starting 12 hours before bariatric surgery, may reduce the incidence of VTE (low‐certainty evidence). However, we could not assess the effect of this intervention on the incidence of major bleeding, PE, death or adverse events. </p> <p>We were unable to assess the effect of any intervention on quality of life.</p> </section> <h3 class="title" id="CD013683-sec-0122">Implications for research</h3> <section id="CD013683-sec-0122"> <p>We found limited evidence on the use of heparins, pentasaccharides and mechanical combined with pharmacological prophylaxis in people undergoing bariatric surgery. Given the low number of included studies and the low number of events in each study, there is a need for high‐quality randomised controlled trials (RCTs) with larger sample sizes. Future trials must be sufficiently large to assess all relevant clinical outcomes, particularly those that occur less frequently (e.g. PE, mortality and adverse events). With the aim of improving clinical practice, future trials should also assess the effect of the interventions on participants' quality of life. Moreover, there is a lack of evidence regarding other relevant interventions, such as direct oral anticoagulants and antiplatelet agents for people undergoing bariatric surgery. </p> <p>Research is needed on the ideal duration of the intervention (i.e. the duration of prophylactic anticoagulation) based on VTE pathophysiology. In addition, new RCTs should follow up participants for at least 120 days. Although this time point is arbitrary, there is a need to assess the long‐term outcomes related to anticoagulation. </p> <p>Evidence from the five ongoing studies we identified in our search may be more robust; we will add all relevant data to updates of this review. There is still a need for RCTs of high methodological quality, including adequate reporting of randomisation, allocation concealment and blinding. </p> <p>The key outcomes to be measured are VTE and major bleeding. Other important outcomes are all‐cause mortality, VTE‐related mortality, PE, DVT, adverse events and quality of life. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013683-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013683-sec-0008"></div> <div class="table" id="CD013683-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Higher‐dose heparin compared to standard‐dose heparin for preventing venous thromboembolism in people undergoing bariatric surgery</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Higher‐dose heparin compared to standard‐dose heparin for preventing venous thromboembolism in people undergoing bariatric surgery</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people undergoing bariatric surgery<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> higher‐dose heparin<br/><b>Comparison:</b> standard‐dose heparin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard‐dose heparin</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with higher‐dose heparin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>VTE</b><br/>Follow‐up: 10–90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>597<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.55</b><br/>(0.05 to 5.99) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(0 to 43) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b><br/>Follow‐up: 10–90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>597<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.19</b><br/>(0.48 to 2.96) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 per 1000<br/>(19 to 118) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: 10–90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>597<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>4 studies reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VTE‐related mortality</b><br/>Follow‐up: 10–90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>597<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>4 studies reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>PE</b><br/>Follow‐up: up to 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>310<br/>(2 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.37</b><br/>(0.02 to 8.92) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(0 to 55) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DVT</b><br/>Follow‐up: 10–90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>597<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.10</b><br/>(0.07 to 17.40) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(0 to 63) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events (thrombocytopenia)</b><br/>Follow‐up: up to 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>310<br/>(2 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.10</b><br/>(0.07 to 17.40) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/>(0 to 108) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>DVT:</b> deep vein thrombosis; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to high risk of performance and detection bias.<br/><sup>b</sup>Downgraded one level due to imprecision: few events and 95% CI consistent with possible benefit and possible harm.<br/><sup>c</sup>Downgraded two levels due to imprecision: no events.<br/><sup>d</sup>Downgraded two levels due to imprecision: very large CI of the absolute difference and few events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013683-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Heparin compared to pentasaccharide for preventing venous thromboembolism in people undergoing bariatric surgery</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Heparin compared to pentasaccharide for preventing venous thromboembolism in people undergoing bariatric surgery</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people undergoing bariatric surgery<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> heparin<br/><b>Comparison:</b> pentasaccharide </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with pentasaccharide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with heparin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>VTE</b><br/>Follow‐up: up to 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>175<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.83</b><br/>(0.19 to 3.61) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/>(8 to 157) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b><br/>Follow‐up: up to 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>198<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.70</b><br/>(0.42 to 6.92) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 per 1000<br/>(13 to 208) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: up to 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>198<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1 study reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VTE‐related mortality</b><br/>Follow‐up: up to 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>198<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1 study reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PE</b><br/>Follow‐up: up to 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>198<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1 study reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DVT</b><br/>Follow‐up: up to 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>175<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.83</b><br/>(0.19 to 3.61) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/>(8 to 157) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events (thrombocytopenia)</b><br/>Follow‐up: up to 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>198<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.34</b><br/>(0.01 to 8.25) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> <p>(0 to 83)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>DVT:</b> deep vein thrombosis; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to high risk of reporting and other bias.<br/><sup>b</sup>Downgraded one level due to imprecision: few participants, and 95% CI consistent with possible benefit and possible harm.<br/><sup>c</sup>Downgraded two levels due to imprecision: very large CI of the absolute difference and few events.<br/><sup>d</sup>Downgraded two levels due to imprecision: no events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013683-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Heparin started before compared to after the surgical procedure for preventing venous thromboembolism in people undergoing bariatric surgery</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Heparin started before versus after the surgical procedure for preventing venous thromboembolism in people undergoing bariatric surgery</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people undergoing bariatric surgery<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> heparin started 12 hours before surgery<br/><b>Comparison:</b> heparin started after surgery </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with heparin after surgery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with heparin 12 h before surgery</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>VTE</b><br/>Follow‐up: 15 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.11</b><br/>(0.01 to 2.01) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 per 1000 (1 to 161)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b><br/>Follow‐up: 15 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.00</b><br/>(0.13 to 71.92) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: 15 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1 study reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VTE‐related mortality</b><br/>Follow‐up: 15 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1 study reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PE</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DVT</b><br/>Follow‐up: 15 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.11</b><br/>(0.01 to 2.01) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 per 1000 (1 to 161)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (thrombocytopenia)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>DVT:</b> deep vein thrombosis; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to high risk of performance bias.<br/><sup>b</sup>Downgraded one level due to imprecision: few participants, and 95% CI consistent with possible benefit and possible harm.<br/><sup>c</sup>Downgraded two levels due to imprecision: no events.<br/><sup>d</sup>Downgraded two levels due to imprecision: very large CI of the absolute difference and few events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013683-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Combined mechanical and pharmacological prophylaxis compared to mechanical prophylaxis alone for preventing venous thromboembolism in people undergoing bariatric surgery</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Combined mechanical and pharmacological prophylaxis compared to mechanical prophylaxis alone for preventing venous thromboembolism in people undergoing bariatric surgery</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people undergoing bariatric surgery<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> combined mechanical and pharmacological prophylaxis<br/><b>Comparison:</b> mechanical prophylaxis alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with mechanical prophylaxis alone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with combined mechanical and pharmacological prophylaxis</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>VTE</b><br/>Follow‐up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.05</b><br/>(0.00 to 0.89) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/>(0 to 107) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major bleeding</b><br/>Follow‐up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1 study reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1 study reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VTE‐related mortality</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1 study reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PE</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DVT</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.05</b><br/>(0.00 to 0.89) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/>(0 to 107) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>DVT:</b> deep vein thrombosis; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Number needed to treat for an additional beneficial outcome (NNTB) = 9.<br/><sup>b</sup>Downgraded two levels due to imprecision: few participants and few or no events. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013683-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013683-sec-0009"></div> <p>See <a href="#CD013683-tbl-0005">Table 1</a> for a glossary of terms. </p> <div class="table" id="CD013683-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of terms</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Term</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjustable gastric banding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgical treatment for obesity where a silicone belt or band is placed around the upper portion of the stomach, shaping the stomach in an 'hourglass' form and restricting the flow of food </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticoagulants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drugs that suppress, delay or prevent blood clots</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antiplatelet agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drugs that prevent blood clots by inhibiting platelet function</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Atherosclerosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A disease characterised by a build‐up of abnormal fat, cholesterol and platelet deposits on the inner wall of the arteries </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biliopancreatic diversion with duodenal switch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgical treatment for obesity that involves reducing the size of the stomach by removing some of it, then bypassing most of the intestine </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body mass index (BMI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body mass divided by the square of the body height, universally expressed in units of kg/m<sup>2</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bariatric surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any type of surgery aimed at weight loss</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deep vein thrombosis (DVT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coagulation or clotting of the blood in a deep vein (i.e. far beneath the surface of the skin) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duplex ultrasound</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐invasive evaluation of blood flow through the arteries and veins by ultrasound devices </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dyslipidaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abnormal concentration of fats (lipids or lipoproteins) in the blood</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastric imbrication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Also known as stomach folding; surgical procedure to reduce the stomach volume without resection </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A drug used to prevent blood clotting (anticoagulant, blood thinner)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laparoscopic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A procedure performed via an endoscope inserted through an incision in the abdominal wall and used for viewing or performing minor surgery in the abdominal or pelvic cavities </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐molecular‐weight heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A drug used to prevent blood clotting (anticoagulant)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Obesity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Where the amount of body fat is beyond healthy conditions (BMI greater than 30 kg/m<sup>2</sup>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excess watery fluid that collects in tissues of the body, causing swelling when fluid leaks out of the body's vessels </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overweight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Where the amount of body fat is over that of the average population, but less than unhealthy conditions (BMI between 25 kg/m<sup>2</sup> and 30 kg/m<sup>2</sup>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Substance or treatment with no active effect, like a sugar pill</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary embolism (PE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood clot in the lung or blood vessel leading to the lung. The clot originates in a vein (e.g. DVT) and travels to the lung. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised clinical trial (RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A study in which the participants are divided randomly into separate groups to compare different treatments </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roux‐en‐Y gastric bypass</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgical treatment for obesity where the surgeon creates a small pouch at the top of the stomach, limiting the amount of food that can be eaten. The small intestine is also cut and connected to the new pouch. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Superficial thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inflammatory thrombotic disorder in which a clot develops in a vein near the surface of the skin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleeve gastrectomy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bariatric surgery in which most of the stomach is removed, leaving a small sleeve</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local coagulation of blood (clot) in a part of the circulatory system</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unfractionated heparin (UFH)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A mixture of heparins obtained from animals that is used to prevent blood coagulation, to prevent and treat clotting disorders </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vascular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relating to blood vessels (arteries and veins)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vena cava</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The largest human vein that returns blood to the heart after it has passed around the body </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relating to a vein</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venous thromboembolism (VTE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A condition that involves a blood clot forming in a vein, and sometimes migrating to another location (e.g. the lung) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Virchow's Triad</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 factors that contribute to thrombosis:</p> <p> <ul id="CD013683-list-0001"> <li> <p>changes in the vessel wall;</p> </li> <li> <p>changes in the pattern of blood flow; and</p> </li> <li> <p>changes in the blood constituents (hypercoagulability).</p> </li> </ul> </p> </td> </tr> </tbody> </table> </div> <section id="CD013683-sec-0010"> <h3 class="title" id="CD013683-sec-0010">Description of the condition</h3> <p>Obesity is clinically defined as a body mass index (BMI) of 30 kg/m<sup>2</sup> or greater; a BMI of 40 kg/m<sup>2</sup> or greater is called severe obesity or morbid obesity (<a href="./references#CD013683-bbs2-0096" title="World Health Organization. Obesity: preventing and managing the global epidemic. apps.who.int/iris/handle/10665/42330 (accessed 11 January 2019).">WHO 1998</a>). The BMI is calculated by dividing the weight of an individual in kilograms by the square of their height in metres. Although there are other clinical definitions of obesity, BMI is the most widely used due to its ease of application in clinical practice (<a href="#CD013683-tbl-0006">Table 2</a>). The causes of obesity are multifactorial and include direct and indirect effects such as genetics, gene‐environment interactions and social determinants of health (e.g. area of residence, educational status and economic stability); however, the most important factor is an energy imbalance between physical activity and food intake (<a href="./references#CD013683-bbs2-0026" title="Arroyo-JohnsonC , MinceyKD . Obesity epidemiology worldwide. Gastroenterology Clinics of North America2016;45(4):571-9. [PMID: 27837773]">Arroyo‐Johnson 2016</a>). Increased food industry productivity through technological development has led to a concomitant increase in the energy value of commonly consumed foods. At the same time, improvements in transport have resulted in a more sedentary lifestyle. These factors are often cited as the main reasons for the constant increase in BMI and obesity worldwide (<a href="./references#CD013683-bbs2-0069" title="MedinaC , Tolentino-MayoL , Lopez-RidauraR , BarqueraS . Evidence of increasing sedentarism in Mexico City during the last decade: sitting time prevalence, trends, and associations with obesity and diabetes. PLOS One2017;12(12):e0188518. [PMID: 29194458]">Medina 2017</a>). Since the mid‐1970s, the prevalence of obesity has tripled (from 3.2% in 1975 to 10.8% in 2014 in men, and from 6.4% in 1975 to 14.9% in 2014 in women); if this trend continues, it is estimated that by 2025 obesity will affect around 18% of men and 21% of women worldwide (<a href="./references#CD013683-bbs2-0071" title="NCD Risk Factor Collaboration (NCD-RisC), Di CesareM , BenthamJ , StevensGA , ZhouB , DanaeiG , et al. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet2016;387(10026):1377-96. [PMID: 27115820]">NCD‐RisC 2016</a>). In the USA, it is estimated that 69% of all adults are overweight and 35% are obese (<a href="./references#CD013683-bbs2-0073" title="American College of Cardiology/American Heart Association Task Force. Expert Panel Report: Guidelines (2013) for the management of overweight and obesity in adults. Obesity2014;22(Suppl 2):S41-410. [PMID: 24227637]">NHLBI 2013</a>). </p> <div class="table" id="CD013683-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Classification of adults according to BMI</span></div> <tbody> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Classification</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>BMI values<sup>a</sup> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Underweight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 18.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Normal range</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5–24.99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Overweight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Preobese</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.00–29.99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Obese class I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.00–34.99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Obese class II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.00–39.99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Obese class Ill</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 40</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BMI: body mass index.</p> <p><sup>a</sup>Body mass divided by the square of the body height, universally expressed in units of kg/m<sup>2</sup>.These BMI values are age‐ and sex‐independent. </p> </div> </div> <p>Obesity and high BMI are associated with pathologies such as type 2 diabetes and dyslipidaemia, as well as various cancers and cardiovascular diseases (including hypertension, atherosclerosis, stroke, venous thromboembolism and coronary disease; <a href="./references#CD013683-bbs2-0049" title="FresanU , SabateJ , Martinez-GonzalezMA , Segovia-SiapcoG , dela Fuente-ArrillagaC , Bes-RastrolloM . Adherence to the 2015 dietary guidelines for Americans and mortality risk in a Mediterranean cohort: the SUN project. Preventive Medicine2019;118:317-24. [PMID: 30468792]">Fresan 2019</a>). One study that examined adherence to the 2015–2020 Dietary Guidelines for Americans in a Spanish population of almost 17,000 people found that high adherence scores were associated with reduced risk for all‐cause mortality, cardiovascular mortality and cancer mortality (<a href="./references#CD013683-bbs2-0049" title="FresanU , SabateJ , Martinez-GonzalezMA , Segovia-SiapcoG , dela Fuente-ArrillagaC , Bes-RastrolloM . Adherence to the 2015 dietary guidelines for Americans and mortality risk in a Mediterranean cohort: the SUN project. Preventive Medicine2019;118:317-24. [PMID: 30468792]">Fresan 2019</a>). These conditions lead to increased health costs, and it is estimated that obesity and high BMI were responsible for the 10% annual increase in health costs in the USA from 1995 to 2008. In 2006, people with obesity had a 42% greater annual per capita spending than those without obesity (<a href="./references#CD013683-bbs2-0044" title="FinkelsteinEA , TrogdonJG , CohenJW , DietzW . Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Affairs2009;28(5):w822-31. [PMID: 19635784]">Finkelstein 2009</a>). </p> <p>Since the 1990s, a number of surgical techniques (i.e. bariatric surgery) have been developed to treat obesity. Usually, they are indicated for people with severe obesity (BMI of 40 kg/m<sup>2</sup> or greater, or 30 kg/m<sup>2</sup> or greater with comorbidities), although some studies use 35 kg/m<sup>2</sup> as the threshold (<a href="./references#CD013683-bbs2-0073" title="American College of Cardiology/American Heart Association Task Force. Expert Panel Report: Guidelines (2013) for the management of overweight and obesity in adults. Obesity2014;22(Suppl 2):S41-410. [PMID: 24227637]">NHLBI 2013</a>). Different studies have shown these procedures to be more effective than clinical treatments alone, in people eligible to undergo surgical treatment (<a href="./references#CD013683-bbs2-0036" title="ColquittJL , PickettK , LovemanE , FramptonGK . Surgery for weight loss in adults. Cochrane Database of Systematic Reviews2014, Issue 8. Art. No: CD003641. [DOI: 10.1002/14651858.CD003641.pub4]">Colquitt 2014</a>; <a href="./references#CD013683-bbs2-0079" title="RegesO , GreenlandP , DickerD , LeibowitzM , HoshenM , GoferI , et al. Association of bariatric surgery using laparoscopic banding, Roux-en-Y gastric bypass, or laparoscopic sleeve gastrectomy vs usual care obesity management with all-cause mortality. JAMA2018;319(3):279-90. [PMID: 29340677]">Reges 2018</a>). The term 'bariatric' refers to treatments that aim to reduce weight and, therefore, treat obesity. Although 'bariatric' can refer to any treatment, either clinical or surgical, its use became popular after the 1960s, when the first surgical procedures for obesity came into practice (<a href="./references#CD013683-bbs2-0053" title="Historic use of the word BARIATRIC, since 1800. Google Books Ngram Viewer (accessed 9 July 2020);Available from tinyurl.com/y7ech3cv.">Google Ngram Viewer 2018</a>). Bariatric surgery comprises surgical techniques that result in reduced alimentary intake or absorption (or both), through restriction of the stomach or digestive tract (or both). Some of the most common techniques include laparoscopic or open Roux‐en‐Y gastric bypass, laparoscopic adjustable gastric banding (although the use of this technique has decreased since the 2010s), laparoscopic sleeve gastrectomy, biliopancreatic diversion with duodenal switch, and laparoscopic gastric imbrication (<a href="./references#CD013683-bbs2-0036" title="ColquittJL , PickettK , LovemanE , FramptonGK . Surgery for weight loss in adults. Cochrane Database of Systematic Reviews2014, Issue 8. Art. No: CD003641. [DOI: 10.1002/14651858.CD003641.pub4]">Colquitt 2014</a>; <a href="./references#CD013683-bbs2-0077" title="PuzziferriN , AlmandozJP . Sleeve gastrectomy for weight loss. JAMA2018;319(3):316. [PMID: 29340681]">Puzziferri 2018</a>). </p> <p>Research has shown bariatric surgery to be safe, as overall mortality after the procedure is between 0.05% and 1.5% or 2% (<a href="./references#CD013683-bbs2-0072" title="NguyenNT , VarelaJE . Bariatric surgery for obesity and metabolic disorders: state of the art. Nature Reviews. Gastroenterology and Hepatology2017;14(3):160-9. [PMID: 27899816]">Nguyen 2017</a>). However, when surgical complications do occur, they can be life‐threatening. One such complication is venous thromboembolism (VTE; <a href="./references#CD013683-bbs2-0036" title="ColquittJL , PickettK , LovemanE , FramptonGK . Surgery for weight loss in adults. Cochrane Database of Systematic Reviews2014, Issue 8. Art. No: CD003641. [DOI: 10.1002/14651858.CD003641.pub4]">Colquitt 2014</a>; <a href="./references#CD013683-bbs2-0052" title="GoldfederLB , RenCJ , GillJR . Fatal complications of bariatric surgery. Obesity Surgery2006;16(8):1050-6. [PMID: 16901359]">Goldfeder 2006</a>; <a href="./references#CD013683-bbs2-0070" title="MorinoM , ToppinoM , ForestieriP , AngrisaniL , AllaixME , ScopinaroN . Mortality after bariatric surgery: analysis of 13,871 morbidly obese patients from a national registry. Annals of Surgery2007;246(6):1002-7; discussion 1007-9. [PMID: 18043102]">Morino 2007</a>). </p> <p>VTE comprises two related diseases: deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE has an estimated annual incidence of 100 to 200 persons per 100,000, depending on phenotype, age and sex (<a href="./references#CD013683-bbs2-0056" title="HeitJA . Epidemiology of venous thromboembolism. Nature Reviews Cardiology2015;12(8):464-74. [PMID: 26076949]">Heit 2015</a>; <a href="./references#CD013683-bbs2-0062" title="JacobsB , HenkePK . Evidence-based therapies for pharmacologic prevention and treatment of acute deep vein thrombosis and pulmonary embolism. Surgical Clinics of North America2018;98(2):239-53. [PMID: 29502769]">Jacobs 2018</a>). It is the third leading cause of cardiovascular death worldwide, and the leading cause of preventable death in hospitalised people (<a href="./references#CD013683-bbs2-0052" title="GoldfederLB , RenCJ , GillJR . Fatal complications of bariatric surgery. Obesity Surgery2006;16(8):1050-6. [PMID: 16901359]">Goldfeder 2006</a>). Usually, VTE begins as an episode of DVT (with or without symptoms) that may lead to complications. PE can occur as a complication of a DVT or as a primary event of VTE, and is associated with a high risk of death; while chronic complications related to DVT, including post‐thrombotic syndrome (PTS) or chronic pulmonary hypertension (CPH), can have a considerable impact on quality of life (QoL; <a href="./references#CD013683-bbs2-0028" title="BarnesGD , KanthiY , FroehlichJB . Venous thromboembolism: predicting recurrence and the need for extended anticoagulation. Vascular Medicine2015;20(2):143-52. [PMID: 25832602]">Barnes 2015</a>). The risk of VTE is higher in surgical patients, representing the third most common cause of mortality; and VTE incidence is further increased in people with obesity (<a href="./references#CD013683-bbs2-0031" title="BorchKH , BraekkanSK , MathiesenEB , NjolstadI , WilsgaardT , StormerJ , et al. Anthropometric measures of obesity and risk of venous thromboembolism: the Tromso study. Arteriosclerosis, Thrombosis and Vascular Biology2010;30(1):121-7. [PMID: 19834110]">Borch 2010</a>). Consequently, VTE is of particular concern for people undergoing bariatric surgery; it is responsible for considerable morbidity and accounts for almost 50% of postoperative mortality in this population (<a href="./references#CD013683-bbs2-0070" title="MorinoM , ToppinoM , ForestieriP , AngrisaniL , AllaixME , ScopinaroN . Mortality after bariatric surgery: analysis of 13,871 morbidly obese patients from a national registry. Annals of Surgery2007;246(6):1002-7; discussion 1007-9. [PMID: 18043102]">Morino 2007</a>). </p> <p>The incidence of VTE in surgical patients varies according to the type of surgery and patient profile. Orthopaedic procedures have higher rates (40% to 60%) compared to other surgery (15% to 40%; <a href="./references#CD013683-bbs2-0051" title="GeertsWH , PineoGF , HeitJA , BergqvistD , LassenMR , ColwellCW , et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest2004;126(3 Suppl):338S-400S. [PMID: 15383478]">Geerts 2004</a>). Some other clinical conditions have increased the risk of VTE in hospitalised people. For example, 49% of hospitalised people who are severely ill with COVID‐19 will develop VTE, compared to 11.2% of all hospitalised people (<a href="./references#CD013683-bbs2-0038" title="COVIDSurg Collaborative, GlobalSurg Collaborative. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study. Anaesthesia2022;77(1):28-39. [DOI: 10.1111/anae.15563]">COVIDSurg 2022</a>; <a href="./references#CD013683-bbs2-0046" title="FlumignanRL , TinôcoJD , PascoalPI , AreiasLL , CossiMS , FernandesMI , et al. Prophylactic anticoagulants for people hospitalized with COVID-19: systematic review. British Journal of Surgery2021;108(9):e299-300. [DOI: 10.1093/bjs/znab197]">Flumignan 2021</a>; <a href="./references#CD013683-bbs2-0047" title="FlumignanRL , CivileVT , TinôcoJD , PascoalPI , AreiasLL , MatarCF , et al. Anticoagulants for people hospitalised with COVID-19. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD013739. [DOI: 10.1002/14651858.CD013739.pub2]">Flumignan 2022a</a>; <a href="./references#CD013683-bbs2-0083" title="SantosBC , FlumignanRL , CivileVT , AtallahAN , NakanoLC . Prophylactic anticoagulants for non-hospitalised people with COVID-19. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD015102. [DOI: 10.1002/14651858.CD015102]">Santos 2022</a>). Additionally, in people with COVID‐19, 30‐day mortality is 7.4% in those without VTE compared with 40.8% in those with VTE (<a href="./references#CD013683-bbs2-0038" title="COVIDSurg Collaborative, GlobalSurg Collaborative. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study. Anaesthesia2022;77(1):28-39. [DOI: 10.1111/anae.15563]">COVIDSurg 2022</a>). Some guidelines recommend various agents for VTE prophylaxis (preventive treatment) in surgical patients and also recommend extended prophylaxis (30 days) in people undergoing orthopaedic surgery (<a href="./references#CD013683-bbs2-0043" title="Falck-YtterY , FrancisCW , JohansonNA , CurleyC , DahlOE , SchulmanS , et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e278S-325S. [PMID: 22315265]">Falck‐Ytter 2012</a>). </p> <p>The economic impact associated with VTE is significant and can be up to 1.5 times greater for surgical patients (<a href="./references#CD013683-bbs2-0082" title="SalousAK , ReyadA , SweeneyK , MavanurA . A significant proportion of venous thromboembolism events in general surgical patients occurs after discharge: analysis of the ACS-NSQIP Essentials database. Perioperative Medicine2019;8:18. [PMID: 31890156]">Salous 2019</a>). This difference in total cost occurs mainly in the first three months after confirmation of VTE (<a href="./references#CD013683-bbs2-0035" title="CohoonKP , LeibsonCL , RansomJE , AshraniAA , PettersonTM , LongKH , et al. Costs of venous thromboembolism associated with hospitalization for medical illness. American Journal of Managed Care2015;21(4):e255-63. [PMID: 26244788]">Cohoon 2015</a>). </p> </section> <section id="CD013683-sec-0011"> <h3 class="title" id="CD013683-sec-0011">Description of the intervention</h3> <p>Interventions for the prevention of VTE all aim to affect one of the elements of Virchow's Triad (see <a href="#CD013683-tbl-0005">Table 1</a>). Although vena cava filters are not recommended for primary VTE prevention (<a href="./references#CD013683-bbs2-0054" title="GouldMK , GarciaDA , WrenSM , KaranicolasPJ , ArcelusJI , HeitJA , et al. Prevention of VTE in non-orthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e227S-77S. [PMID: 22315263]">Gould 2012</a>), there are mechanical interventions (e.g. elastic stockings, pneumatic compression, early ambulation, vein recanalisation treatments) to reduce venous stasis (<a href="./references#CD013683-bbs2-0032" title="BroderickC , WatsonL , ArmonMP . Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb. Cochrane Database of Systematic Reviews2021, Issue 1. Art. No: CD002783. [DOI: 10.1002/14651858.CD002783.pub5] [PMID: 33464575]">Broderick 2021</a>; <a href="./references#CD013683-bbs2-0045" title="FlumignanRL , FlumignanCD , Baptista-SilvaJC . Angioplasty for deep venous thrombosis. Cochrane Database of Systematic Reviews2015, Issue 1. Art. No: CD011468. [DOI: 10.1002/14651858.CD011468]">Flumignan 2015</a>; <a href="./references#CD013683-bbs2-0092" title="StreiffMB , AgnelliG , ConnorsJM , CrowtherM , EichingerS , LopesR , et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. Journal of Thrombosis and Thrombolysis2016;41(1):32-67. [PMID: 26780738]">Streiff 2016</a>). Pharmacological interventions (anticoagulants or antiplatelet agents) focus on reducing the hypercoagulability factor (<a href="./references#CD013683-bbs2-0024" title="AgenoW . Recent advances in the management of venous thromboembolism. Korean Journal of Hematology2010;45(1):8-13. [PMID: 21120157]">Ageno 2010</a>; <a href="./references#CD013683-bbs2-0046" title="FlumignanRL , TinôcoJD , PascoalPI , AreiasLL , CossiMS , FernandesMI , et al. Prophylactic anticoagulants for people hospitalized with COVID-19: systematic review. British Journal of Surgery2021;108(9):e299-300. [DOI: 10.1093/bjs/znab197]">Flumignan 2021</a>; <a href="./references#CD013683-bbs2-0047" title="FlumignanRL , CivileVT , TinôcoJD , PascoalPI , AreiasLL , MatarCF , et al. Anticoagulants for people hospitalised with COVID-19. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD013739. [DOI: 10.1002/14651858.CD013739.pub2]">Flumignan 2022a</a>; <a href="./references#CD013683-bbs2-0048" title="FlumignanCD , FlumignanRL , Baptista-SilvaJC . Antiplatelet agents for the treatment of deep venous thrombosis. Cochrane Database of Systematic Reviews2022, Issue 9. Art. No: CD012369. [DOI: 10.1002/14651858.CD012369.pub2]">Flumignan 2022b</a>; <a href="./references#CD013683-bbs2-0083" title="SantosBC , FlumignanRL , CivileVT , AtallahAN , NakanoLC . Prophylactic anticoagulants for non-hospitalised people with COVID-19. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD015102. [DOI: 10.1002/14651858.CD015102]">Santos 2022</a>). The decision of whether to use prophylaxis (mechanical or pharmacological, or both) depends on the risk stratification of each person according to criteria such as the Rogers or Caprini score (<a href="./references#CD013683-bbs2-0054" title="GouldMK , GarciaDA , WrenSM , KaranicolasPJ , ArcelusJI , HeitJA , et al. Prevention of VTE in non-orthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e227S-77S. [PMID: 22315263]">Gould 2012</a>), or the National Institute for Health and Care Excellence (NICE) risk assessment tool for VTE (<a href="./references#CD013683-bbs2-0074" title="National Institute for Health and Care Excellence. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89). Available from www.nice.org.uk/guidance/ng89 (accessed 5 April 2020).">NICE 2018</a>). </p> <p>The latest guidelines from the American College of Chest Physicians recommend mechanical prophylaxis in all surgical patients (at least early ambulation), and pharmacological prophylaxis in those with a moderate or high risk of VTE and low or moderate risk of major bleeding (<a href="./references#CD013683-bbs2-0041" title="DouketisJD . The 2016 American College of Chest Physicians treatment guidelines for venous thromboembolism: a review and critical appraisal. Internal and Emergency Medicine2016;11(8):1031-5. [PMID: 27766542]">Douketis 2016</a>). One Cochrane Review found that combining pharmacological prophylaxis with intermittent pneumatic compression resulted in a reduced incidence of VTE compared with intermittent pneumatic compression alone, but increased the incidence of major bleeding (<a href="./references#CD013683-bbs2-0064" title="KakkosS , KirkilesisG , CapriniJA , GeroulakosG , NicolaidesA , StansbyG , et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism. Cochrane Database of Systematic Reviews2022, Issue 1. Art. No: CD005258. [DOI: 10.1002/14651858.CD005258.pub4]">Kakkos 2022</a>). People undergoing bariatric surgery are considered to have at least moderate risk of a VTE event (<a href="./references#CD013683-bbs2-0029" title="BartlettMA , MauckKF , DanielsPR . Prevention of venous thromboembolism in patients undergoing bariatric surgery. Vascular Health and Risk Management2015;11:461-77. [PMID: 26316771]">Bartlett 2015</a>), and should therefore receive pharmacological prophylaxis. </p> <p>For the purpose of this review, we focused on pharmacological interventions for the prevention of VTE in people undergoing bariatric surgery. </p> </section> <section id="CD013683-sec-0012"> <h3 class="title" id="CD013683-sec-0012">How the intervention might work</h3> <p>Drugs available for the prevention of VTE are oral anticoagulants (OACs), heparins (either unfractionated or low‐molecular‐weight), direct oral anticoagulants (DOACs), pentasaccharides and antiplatelet agents (<a href="./references#CD013683-bbs2-0046" title="FlumignanRL , TinôcoJD , PascoalPI , AreiasLL , CossiMS , FernandesMI , et al. Prophylactic anticoagulants for people hospitalized with COVID-19: systematic review. British Journal of Surgery2021;108(9):e299-300. [DOI: 10.1093/bjs/znab197]">Flumignan 2021</a>; <a href="./references#CD013683-bbs2-0047" title="FlumignanRL , CivileVT , TinôcoJD , PascoalPI , AreiasLL , MatarCF , et al. Anticoagulants for people hospitalised with COVID-19. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD013739. [DOI: 10.1002/14651858.CD013739.pub2]">Flumignan 2022a</a>; <a href="./references#CD013683-bbs2-0062" title="JacobsB , HenkePK . Evidence-based therapies for pharmacologic prevention and treatment of acute deep vein thrombosis and pulmonary embolism. Surgical Clinics of North America2018;98(2):239-53. [PMID: 29502769]">Jacobs 2018</a>; <a href="./references#CD013683-bbs2-0063" title="KakkosSK , GohelM , BaekgaardN , BauersachsR , Bellmunt-MontoyaS , BlackSA , et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the management of venous thrombosis. European Journal of Vascular and Endovascular Surgery2021;61(1):9-82. [PMID: 10.1016/j.ejvs.2020.09.023]">Kakkos 2021</a>; <a href="./references#CD013683-bbs2-0083" title="SantosBC , FlumignanRL , CivileVT , AtallahAN , NakanoLC . Prophylactic anticoagulants for non-hospitalised people with COVID-19. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD015102. [DOI: 10.1002/14651858.CD015102]">Santos 2022</a>; <a href="./references#CD013683-bbs2-0091" title="StevensSM , WollerSC , KreuzigerLB , BounameauxH , DoerschugK , GeersingGJ , et al. Antithrombotic Therapy for VTE Disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):e545-608. [PMID: 10.1016/j.chest.2021.07.055]">Stevens 2021</a>). </p> <p>Warfarin and coumarin agents are classified as OACs, and are also called antivitamin K agents because they act as competitive antagonists of vitamin K. They have been used in clinical practice since 1954, and are therefore the standard comparison agent for almost every trial that investigates VTE treatment (<a href="./references#CD013683-bbs2-0088" title="SmithM , WakamG , WakefieldT , ObiA . New trends in anticoagulation therapy. Surgical Clinics of North America2018;98(2):219-38. [PMID: 29502768]">Smith 2018</a>). Because OACS are associated with an increased risk of major bleeding and take longer to reach effective plasma levels, their use in primary prophylaxis is limited; these agents have more utility in the long‐term treatment and prevention of VTE recurrence (<a href="./references#CD013683-bbs2-0091" title="StevensSM , WollerSC , KreuzigerLB , BounameauxH , DoerschugK , GeersingGJ , et al. Antithrombotic Therapy for VTE Disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):e545-608. [PMID: 10.1016/j.chest.2021.07.055]">Stevens 2021</a>). </p> <p>Low‐molecular‐weight heparins (LMWHs) present a lower risk of bleeding and a higher effectiveness compared with unfractionated heparins (UFHs) in DVT treatment. However, in VTE prevention, this difference appears to be irrelevant (<a href="./references#CD013683-bbs2-0054" title="GouldMK , GarciaDA , WrenSM , KaranicolasPJ , ArcelusJI , HeitJA , et al. Prevention of VTE in non-orthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e227S-77S. [PMID: 22315263]">Gould 2012</a>). </p> <p>DOACs are the most recent class of anticoagulants to be released for medical use. They are direct inhibitors of factors IIa or Xa of the coagulation cascade and are similar in effectiveness and safety to LMWHs (<a href="./references#CD013683-bbs2-0034" title="BurnettAE , MahanCE , VazquezSR , OertelLB , GarciaDA , AnsellJ . Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. Journal of Thrombosis and Thrombolysis2016;41(1):206-32. [PMID: 26780747]">Burnett 2016</a>; <a href="./references#CD013683-bbs2-0091" title="StevensSM , WollerSC , KreuzigerLB , BounameauxH , DoerschugK , GeersingGJ , et al. Antithrombotic Therapy for VTE Disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):e545-608. [PMID: 10.1016/j.chest.2021.07.055]">Stevens 2021</a>). The risk of bleeding in people with DVT is lower with DOACs compared with vitamin K antagonists (VKAs), and some randomised controlled trials (RCTs) have reported a reduced risk of recurrent VTE with DOACs (<a href="./references#CD013683-bbs2-0091" title="StevensSM , WollerSC , KreuzigerLB , BounameauxH , DoerschugK , GeersingGJ , et al. Antithrombotic Therapy for VTE Disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):e545-608. [PMID: 10.1016/j.chest.2021.07.055]">Stevens 2021</a>). Nevertheless, DOACs are rarely used in studies of VTE prophylaxis in non‐orthopaedic surgery, and the ninth edition of the American College of Chest Physicians' evidence‐based clinical practice guidelines includes no recommendations for their use in VTE prophylaxis (<a href="./references#CD013683-bbs2-0054" title="GouldMK , GarciaDA , WrenSM , KaranicolasPJ , ArcelusJI , HeitJA , et al. Prevention of VTE in non-orthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e227S-77S. [PMID: 22315263]">Gould 2012</a>). </p> <p>Pentasaccharides are a relatively new class of anticoagulants and are indirect inhibitors of factor Xa. One Cochrane Review of pentasaccharides for the prevention of VTE showed increased effectiveness for prevention of total VTE, total DVT, PE and symptomatic VTE (<a href="./references#CD013683-bbs2-0040" title="DongK , SongY , LiX , DingJ , GaoZ , LuD , et al. Pentasaccharides for the prevention of venous thromboembolism. Cochrane Database of Systematic Reviews2016, Issue 10. Art. No: CD005134. [DOI: 10.1002/14651858.CD005134.pub3]">Dong 2016</a>). However, these anticoagulants did not affect mortality rate and increased the risk of major bleeding. Most of the included trials involved orthopaedic patients, so provided no evidence of the benefits and safety of pentasaccharides in other surgical patients, including those undergoing bariatric surgery (<a href="./references#CD013683-bbs2-0040" title="DongK , SongY , LiX , DingJ , GaoZ , LuD , et al. Pentasaccharides for the prevention of venous thromboembolism. Cochrane Database of Systematic Reviews2016, Issue 10. Art. No: CD005134. [DOI: 10.1002/14651858.CD005134.pub3]">Dong 2016</a>). </p> <p>Although it is not common practice, the use of antiplatelets for the prevention of DVT might be considered in certain conditions, as they interfere with Virchow's Triad (see <a href="#CD013683-tbl-0005">Table 1</a>; <a href="./references#CD013683-bbs2-0042" title="EikelboomJW , HirshJ , SpencerFA , BaglinTP , WeitzJI . Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e89S-e119S. [PMID: 22315278]">Eikelboom 2012</a>). Data regarding the effects of antiplatelets are lacking. While one Cochrane Review has evaluated the effects of antiplatelets for DVT treatment, there is no high‐quality evidence on the effectiveness of antiplatelets for VTE prevention (<a href="./references#CD013683-bbs2-0048" title="FlumignanCD , FlumignanRL , Baptista-SilvaJC . Antiplatelet agents for the treatment of deep venous thrombosis. Cochrane Database of Systematic Reviews2022, Issue 9. Art. No: CD012369. [DOI: 10.1002/14651858.CD012369.pub2]">Flumignan 2022b</a>). </p> </section> <section id="CD013683-sec-0013"> <h3 class="title" id="CD013683-sec-0013">Why it is important to do this review</h3> <p>Most strategies aimed at preventing postoperative complications, including VTE, are intended for use in general patients. While this approach can be efficient on a population‐wide basis, the risk‐to‐benefit ratio must be individualised. This is particularly important in populations with specific risk profiles (<a href="./references#CD013683-bbs2-0075" title="PannucciCJ , SwistunL , MacDonaldJK , HenkePK , BrookeBS . Individualized venous thromboembolism risk stratification using the 2005 Caprini score to identify the benefits and harms of chemoprophylaxis in surgical patients: a meta-analysis. Annals of Surgery2017;265(6):1094-103. [PMID: 28106607]">Pannucci 2017</a>). Many people with obesity have some degree of non‐alcoholic liver disease, which may increase the risk of bleeding on some anticoagulants (<a href="./references#CD013683-bbs2-0076" title="PillaiAA , RinellaME . Non-alcoholic fatty liver disease: is bariatric surgery the answer?Clinics in Liver Disease2009;13(4):689-710. [PMID: 19818313]">Pillai 2009</a>; <a href="./references#CD013683-bbs2-0078" title="QamarA , VaduganathanM , GreenbergerNJ , GiuglianoRP . Oral anticoagulation in patients with liver disease. Journal of the American College of Cardiology2018;71(19):2162-75. [PMID: 29747837]">Qamar 2018</a>). In addition, bariatric surgery may cause changes to the anatomy of the gastrointestinal tract, bodyweight and composition of the adipose tissue, all of which can affect the absorption, distribution or elimination of orally administered drugs (<a href="./references#CD013683-bbs2-0068" title="MartinKA , LeeCR , FarrellTM , MollS . Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance. American Journal of Medicine2017;130(5):517-24. [PMID: 28159600]">Martin 2017</a>). </p> <p>Although some guidelines and expert consensus recognise the importance of VTE prevention for people undergoing bariatric surgery, the most widely used guidelines regarding antithrombotic therapy for VTE do not indicate any specific recommendations for this population (<a href="./references#CD013683-bbs2-0034" title="BurnettAE , MahanCE , VazquezSR , OertelLB , GarciaDA , AnsellJ . Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. Journal of Thrombosis and Thrombolysis2016;41(1):206-32. [PMID: 26780747]">Burnett 2016</a>; <a href="./references#CD013683-bbs2-0065" title="KearonC , AklEA , ComerotaAJ , PrandoniP , BounameauxH , GoldhaberSZ , et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e419S-96S. [PMID: 22315268]">Kearon 2012</a>; <a href="./references#CD013683-bbs2-0091" title="StevensSM , WollerSC , KreuzigerLB , BounameauxH , DoerschugK , GeersingGJ , et al. Antithrombotic Therapy for VTE Disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):e545-608. [PMID: 10.1016/j.chest.2021.07.055]">Stevens 2021</a>). The 2018 NICE guideline for preventing VTE has a small section with recommendations regarding bariatric surgery patients, but it has limited information about drugs to be used and no information on dosage or time of administration (<a href="./references#CD013683-bbs2-0074" title="National Institute for Health and Care Excellence. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89). Available from www.nice.org.uk/guidance/ng89 (accessed 5 April 2020).">NICE 2018</a>). While some RCTs have evaluated the use of pharmacological interventions in bariatric surgery, there are currently no high‐quality data for this group (<a href="./references#CD013683-bbs2-0061" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [PMID: 24163189]">Imberti 2014a</a>; <a href="./references#CD013683-bbs2-0087" title="ShelkrotM , MirakaJ , PerezME . Appropriate enoxaparin dose for venous thromboembolism prophylaxis in patients with extreme obesity. Hospital Pharmacy2014;49(8):740-7. [PMID: 25477599]">Shelkrot 2014</a>; <a href="./references#CD013683-bbs2-0089" title="SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [PMID: 25620436]">Steele 2015a</a>). For instance, there are no recommendations on whether prevention should begin before or after surgery, whether the heparin dose must be adjusted for patient mass, or what the duration of pharmacological prophylaxis following a procedure should be (<a href="./references#CD013683-bbs2-0025" title="AminianA , AndalibA , KhorgamiZ , CetinD , BurgueraB , BartholomewJ , et al. Who should get extended thromboprophylaxis after bariatric surgery?: a risk assessment tool to guide indications for post-discharge pharmacoprophylaxis. Annals of Surgery2017;265(1):143-50. [PMID: 28009739]">Aminian 2017</a>; <a href="./references#CD013683-bbs2-0029" title="BartlettMA , MauckKF , DanielsPR . Prevention of venous thromboembolism in patients undergoing bariatric surgery. Vascular Health and Risk Management2015;11:461-77. [PMID: 26316771]">Bartlett 2015</a>; <a href="./references#CD013683-bbs2-0093" title="StrohC , MichelN , LudererD , WolffS , LangeV , KöckerlingF , et al. Risk of thrombosis and thromboembolic prophylaxis in obesity surgery: data analysis from the German Bariatric Surgery Registry. Obesity Surgery2016;26(11):2562-71.">Stroh 2016</a>). We aimed to identify the best available evidence to answer these questions. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013683-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013683-sec-0014"></div> <p>To evaluate the benefits and harms of pharmacological interventions (alone or in combination) on venous thromboembolism and other health outcomes in people undergoing bariatric surgery compared to the same pharmacological intervention administered at a different dose or frequency, the same pharmacological intervention or started at a different time point, another pharmacological intervention, no intervention or placebo. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013683-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013683-sec-0015"></div> <section id="CD013683-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013683-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included all RCTs and quasi‐RCTs that compared pharmacological interventions for preventing VTE in people undergoing bariatric surgery. Parallel (e.g. cluster or individual) and cross‐over designs were eligible for inclusion. We had planned to use data from the first phase of cross‐over studies to avoid the risk of carry‐over effects, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013683-bbs2-0058" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). We included studies published as full‐text articles, those published as abstract only, and unpublished data. </p> </section> <section id="CD013683-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included males and females of all ages who underwent bariatric surgery, with no limitations regarding BMI or surgical technique. We excluded participants receiving treatment for current VTE episodes, and those treated for VTE within the previous 30 days. We considered the rationale for bariatric surgery (see <a href="#CD013683-sec-0028">Data extraction and management</a>), but did not exclude participants based on this criterion. </p> <p>If we had identified studies with mixed populations in which only a subset of the participants met our inclusion criteria, we would have attempted to obtain data for the subgroup of interest from the study authors. Whenever we were unable to obtain data on a subgroup of interest, we would have included all participants in our analysis, providing at least 50% of the study population fulfilled our inclusion criteria. We had planned to explore the effect of this decision in a sensitivity analysis. We would have excluded studies where less than 50% of the population met our inclusion criteria and data on the subgroup of interest were unavailable. </p> </section> <section id="CD013683-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies comparing one pharmacological intervention (agent or drug) versus another pharmacological intervention, placebo or no treatment. Combinations of interventions were also eligible for inclusion, provided co‐treatments were balanced between the treatment and control arms. We also included studies that compared the same drug administered at different doses or frequencies, or started at different time points. We pooled studies that addressed the same comparisons. </p> <p>We considered the following pharmacological interventions:</p> <p> <ul id="CD013683-list-0002"> <li> <p>heparins, both UFHs and LMWHs;</p> </li> <li> <p>VKAs:</p> </li> <li> <p>DOACs, factor Xa inhibitors and direct thrombin inhibitors;</p> </li> <li> <p>antiplatelet agents; and</p> </li> <li> <p>pentasaccharides.</p> </li> </ul> </p> </section> <section id="CD013683-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>All trials that met our inclusion criteria were eligible, regardless of whether they reported one or more of the outcomes listed below. Where a published report did not appear to report one of these outcomes, we accessed the trial protocol and contacted the trial authors to ascertain whether they had measured but not reported any of the outcomes. Relevant trials that measured these outcomes but did not report the data at all, or did not report them in a usable format, would be included in the review and narratively described. Because this was not a cost‐effectiveness review, we had planned to report direct costs data in the discussion section in a narrative form if such information was available. </p> <p>We had planned to present the outcomes at two time points: at 90 days or less after the start of the intervention (early outcomes), and at more than 90 days after the start of the intervention (long‐term outcomes). Early outcomes were of primary interest; therefore, we produced summary of findings tables for this time point only. Long‐term outcomes would be reported at the longest possible time of follow‐up. </p> <section id="CD013683-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013683-list-0003"> <li> <p>VTE (combined DVT or PE, symptomatic or asymptomatic, first episode or recurrent, fatal or non‐fatal). The diagnosis had to be confirmed by clinical examination and at least one additional objective diagnostic test. For DVT diagnosis from any site (e.g. lower limbs, abdominal) these tests included ultrasonography, angiography (e.g. computed tomography (CT), magnetic resonance imaging (MRI) or digital subtraction) and postmortem examination. For PE diagnosis, valid tests were angiography by any described method, ventilation‐perfusion scan or postmortem examination. If the participant had both DVT and PE events, we counted this as a single event of VTE for the analysis of this outcome. </p> </li> <li> <p>Major bleeding, defined by a decrease in haemoglobin concentration of 2 g/dL or more, a retroperitoneal or intracranial bleed, a transfusion of two or more units of blood, or fatal haemorrhagic events, as per the International Society on Thrombosis and Haemostasis (<a href="./references#CD013683-bbs2-0084" title="SchulmanS , AngerasU , BergqvistD , ErikssonB , LassenMR , FisherW . Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. Journal of Thrombosis and Haemostasis2010;8(1):202-4. [PMID: 19878532]">Schulman 2010</a>) </p> </li> </ul> </p> </section> <section id="CD013683-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013683-list-0004"> <li> <p>All‐cause mortality</p> </li> <li> <p>VTE‐related mortality</p> </li> <li> <p>PE (fatal or non‐fatal), confirmed by angiography (e.g. CT, MRI or digital subtraction) or ventilation‐perfusion scan, or both </p> </li> <li> <p>DVT (first episode or recurrent), confirmed by ultrasonography or angiography (e.g. CT, MRI or digital subtraction) </p> </li> <li> <p>Adverse events. We considered all possible adverse events separately, as individual outcomes. These could be gastrointestinal adverse effects (e.g. nausea, vomiting, diarrhoea, abdominal pain), allergic reactions, renal failure, minor bleeding or thrombocytopenia. </p> </li> <li> <p>QoL: participants' subjective perception of improvement (yes or no), as reported by the trial authors or using any validated scoring system such as the 36‐item Short Form Health Survey (SF‐36; <a href="./references#CD013683-bbs2-0095" title="Ware JE Jr, SherbourneCD . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care1992;30(6):473-83. [PMID: 1593914]">Ware 1992</a>) </p> </li> </ul> </p> </section> </section> </section> <section id="CD013683-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013683-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Vascular Information Specialist conducted systematic searches of the following databases for RCTs and controlled clinical trials without language, publication year or publication status restrictions: </p> <p> <ul id="CD013683-list-0005"> <li> <p>Cochrane Vascular Specialised Register via the Cochrane Register of Studies (CRS‐Web; searched 1 November 2021); </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL 2021, Issue 10) via the Cochrane Register of Studies Online (CRSO); </p> </li> <li> <p>MEDLINE (Ovid MEDLINE Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE; 1946 to 1 November 2021); </p> </li> <li> <p>Embase Ovid (1974 to 1 November 2021); and</p> </li> <li> <p>CINAHL EBSCO (1982 to 1 November 2021).</p> </li> </ul> </p> <p>We adapted the search strategy designed for MEDLINE to the other databases. Where appropriate, we combined search strategies with adaptations of the Cochrane highly sensitive search strategy for identifying RCTs and controlled clinical trials (as described in Chapter 4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>; <a href="./references#CD013683-bbs2-0066" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Lefebvre 2021</a>). <a href="./appendices#CD013683-sec-0126">Appendix 1</a> presents the search strategies for the major databases. </p> <p>We searched the following trial registries on 1 November 2021:</p> <p> <ul id="CD013683-list-0006"> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP; <a href="http://www.who.int/clinical-trials-registry-platform" target="_blank">www.who.int/clinical-trials-registry-platform</a>); and </p> </li> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>). </p> </li> </ul> </p> <p>We designed and performed additional searches in Latin American and Caribbean Health Science Information database (LILACS) and Indice Bibliográfico Español de Ciencias de la Salud (IBECS) databases on 16 November 2021, both via Virtual Health Library (<a href="http://bvsalud.org/" target="_blank">bvsalud.org/</a>). We applied no filters and selected the RCTs and quasi‐RCTs manually in the LILACS and IBECS databases. For the search strategy, see <a href="./appendices#CD013683-sec-0127">Appendix 2</a>. </p> </section> <section id="CD013683-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the bibliographies of relevant studies for additional trials, and we also contacted the authors of the included trials for any possible unpublished data. In addition, we contacted field specialists and pharmaceutical companies to enquire about relevant ongoing or unpublished studies. </p> </section> </section> <section id="CD013683-sec-0026"> <h3 class="title" id="CD013683-sec-0026">Data collection and analysis</h3> <section id="CD013683-sec-0027"> <h4 class="title">Selection of studies</h4> <p>We merged the search results to remove duplicate records, then three review authors (FCFA, LCUN and RLGF) independently screened the titles and abstracts of the records using <a href="./references#CD013683-bbs2-0037" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 5 April 2020. Available at covidence.org.">Covidence</a> to determine which were potentially eligible. We resolved any disagreement by discussion within the review team (FCFA, JCCBS, LCUN and RLGF). Finally, we obtained the full‐text reports of all potentially eligible trials and assessed them for compliance with our eligibility criteria. We excluded trials that did not meet the eligibility criteria, documenting the reason for exclusion. We illustrated the study selection process in a PRISMA diagram (<a href="./references#CD013683-bbs2-0067" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Medicine2009;6:e1000100.">Liberati 2009</a>). </p> </section> <section id="CD013683-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (FCFA, LCUN and RLGF) extracted data from the included studies and transferred them to an electronic data extraction form, which had been piloted by two review authors (FCFA and RLGF). Any inconsistencies were resolved by discussion within the review team. We extracted the following data: </p> <p> <ul id="CD013683-list-0007"> <li> <p>publication details (e.g. year, country, authors) and study design;</p> </li> <li> <p>population data (e.g. age, comorbidities, sex, BMI, bariatric surgery technique, rationale for bariatric surgery indication); </p> </li> <li> <p>details of the intervention (e.g. manufacturer, dosage, additional procedures);</p> </li> <li> <p>number of participants randomised into each treatment group, number of participants in each group who failed treatment, numbers of participants lost during follow‐up; </p> </li> <li> <p>duration of follow‐up and cost of treatment; and</p> </li> <li> <p>types and timing of measured outcomes.</p> </li> </ul> </p> <p>One review author (FCFA) transferred data into the Review Manager 5 file (<a href="./references#CD013683-bbs2-0080" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, the Cochrane Collaboration, 2020.">Review Manager 2020</a>). We double‐checked correct data entry by comparing the data presented in the systematic review with the data extraction form. A second review author (RLGF) spot‐checked study characteristics for accuracy against the trial report. </p> </section> <section id="CD013683-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (FCFA, LCUN and RLGF) independently assessed all included studies for risk of bias using the Cochrane risk of bias tool (RoB 1), described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013683-bbs2-0057" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We resolved any disagreements by discussion within the review team. </p> <p>We judged each study as being at high, low or unclear risk of bias for each of the following domains: </p> <p> <ul id="CD013683-list-0008"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective reporting; and</p> </li> <li> <p>other potential threats to validity.</p> </li> </ul> </p> <p>For cluster‐randomised trials, we had planned to consider particular biases as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>: recruitment bias, baseline imbalance, loss of clusters, incorrect analysis and comparability with individually randomised trials (<a href="./references#CD013683-bbs2-0057" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We reported the assessment judgements of each individual study in risk of bias tables (located in the <a href="./references#CD013683-sec-0137" title="">Characteristics of included studies</a> table). We contacted trial author to request missing information whenever we were unable to make judgements based on the published data. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> <section id="CD013683-sec-0030"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol (<a href="./references#CD013683-bbs2-0097" title="AmaralFC , Baptista-SilvaJC , NakanoLC , FlumignanRL . Pharmacological interventions for preventing venous thromboembolism in patients undergoing bariatric surgery. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013683. [DOI: 10.1002/14651858.CD013683]">Amaral 2020</a>) and reported any deviations from it in the <a href="#CD013683-sec-0134">Differences between protocol and review</a> section. </p> </section> </section> <section id="CD013683-sec-0031"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data, we presented the results using risk ratios (RRs) with 95% confidence intervals (CIs). For continuous data, we had planned to present the results as mean differences (MDs) with 95% CIs. Where studies did not use the same scales, we had planned to present the results as standardised mean differences (SMDs) with 95% CIs. </p> <p>We had planned to narratively describe skewed data reported as medians and interquartile ranges. We calculated the number needed to treat (NNT) for the outcomes with direct implication for practice. We obtained the risk difference with Review Manager 5 software (<a href="./references#CD013683-bbs2-0080" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, the Cochrane Collaboration, 2020.">Review Manager 2020</a>). We expressed the NNT as the number needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat for an additional harmful outcome (NNTH), to indicate the direction of effect, as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013683-bbs2-0085" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Schünemann 2019a</a>). </p> </section> <section id="CD013683-sec-0032"> <h4 class="title">Unit of analysis issues</h4> <p>We considered each participant as the unit of analysis. Where included studies considered multiple interventions in the same group, we analysed only the partial data of interest. </p> <section id="CD013683-sec-0033"> <h5 class="title">Cross‐over trials</h5> <p>Had we identified any cross‐over RCTs, we would have used data from the first phase of the study only, to avoid the risk of carry‐over effects, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013683-bbs2-0058" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). </p> </section> <section id="CD013683-sec-0034"> <h5 class="title">Cluster‐randomised trials</h5> <p>We had planned to include cluster‐randomised trials in the analyses along with individually randomised trials, adjusting their sample sizes according to the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013683-bbs2-0058" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). This would involve using an estimate of the intracluster correlation coefficient (ICC) derived from the trial (if possible), or from a similar trial or study of a similar population. If we had used ICCs from other sources, we would have reported this and conducted sensitivity analyses to investigate the effect of variation in the ICC. Had we identified both cluster‐randomised trials and individually randomised trials, we would have synthesised the relevant information. We would have combined the results from both types of trial if there was little heterogeneity between the study designs, and the effect of the intervention appeared unrelated to the choice of randomisation unit. We had also planned to perform a sensitivity analysis to investigate the effects of the randomisation unit. </p> </section> </section> <section id="CD013683-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors or study sponsors to verify key study characteristics. We had planned to obtain missing numerical outcome data where possible (e.g. when we found only the abstract of a study), and use the calculator within Review Manager 5 to calculate missing standard deviations (SDs) using other data from the trial, such as CIs. Where this was not possible, and missing data were thought to introduce serious bias, we had planned to explore the impact of including such studies in the overall assessment of results by a sensitivity analysis. For all outcomes, we followed intention‐to‐treat (ITT) principles to the greatest degree possible (i.e. we analysed participants in their randomised group regardless of what intervention they actually received). We used available case data for the denominator if ITT data were unavailable. </p> </section> <section id="CD013683-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We inspected forest plots visually to consider the direction and magnitude of effects and the degree of overlap between CIs. We used the I<sup>2</sup> statistic to measure heterogeneity among the trials in each analysis, though we acknowledge that there is substantial uncertainty in the value of the I<sup>2</sup> statisticwhen measuring heterogeneity among a small number of studies. Had we identified substantial heterogeneity, we would have reported it and explored possible causes though prespecified subgroup analyses. As strict thresholds for the interpretation of the I<sup>2</sup> statistic are not recommended, we used the rough guide to the interpretation provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013683-bbs2-0039" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Deeks 2019</a>), as follows: </p> <p> <ul id="CD013683-list-0009"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity; and</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>When the I<sup>2</sup> value lay in an area of overlap between two categories (e.g. between 50% and 60%), we considered differences in participants and interventions among the trials contributing data to the analysis (<a href="./references#CD013683-bbs2-0039" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Deeks 2019</a>). </p> </section> <section id="CD013683-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>We performed literature searches in multiple sources to reduce the chance of reporting biases. We would have assessed the presence of publication bias and other reporting bias using funnel plots if we had identified sufficient studies (i.e. more than 10) for inclusion in the meta‐analysis (<a href="./references#CD013683-bbs2-0090" title="SterneJA , EggerM , MoherD , editor(s). Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Sterne 2017</a>). If asymmetry was present, we would have explored possible causes, including publication bias, poor methodological quality and true heterogeneity (<a href="./references#CD013683-bbs2-0090" title="SterneJA , EggerM , MoherD , editor(s). Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Sterne 2017</a>). We had planned to perform additional statistical analysis for continuous outcomes with intervention effects measured as MDs to assess reporting biases, as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013683-bbs2-0090" title="SterneJA , EggerM , MoherD , editor(s). Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Sterne 2017</a>). </p> </section> <section id="CD013683-sec-0038"> <h4 class="title">Data synthesis</h4> <p>We synthesised the data using Review Manager 5 (<a href="./references#CD013683-bbs2-0080" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, the Cochrane Collaboration, 2020.">Review Manager 2020</a>). We undertook meta‐analysis only where it was meaningful (i.e. where the treatments, participants and underlying clinical questions were similar enough for pooling to be appropriate). If we were confident that trials were estimating the same underlying treatment effect (i.e. that the population, interventions, comparators and outcome characteristics of the included studies were homogenous), we used a fixed‐effect meta‐analysis. If clinical heterogeneity had been sufficient to suggest differing underlying treatment effects between trials, or if we had identified at least substantial heterogeneity, we would have used a random‐effects meta‐analysis. Had there been substantial clinical, methodological or statistical heterogeneity across trials that precluded the pooling of data, we would have used a narrative approach to data synthesis (<a href="./references#CD013683-bbs2-0039" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Deeks 2019</a>). </p> <p>We addressed all outcomes listed in <a href="#CD013683-sec-0020">Types of outcome measures</a> in the Results section of the review under the heading <a href="#CD013683-sec-0069">Effects of interventions</a>. In addition, for each comparison, we presented the key outcomes in a summary of findings table. We included the results of individual studies and any statistical summary of these in <a href="./references#CD013683-sec-0124" title="">Data and analyses</a> tables in the review. </p> </section> <section id="CD013683-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>With the available data, we could only perform subgroup analysis for one comparison (higher‐dose heparin versus standard‐dose heparin). However, we plan to perform the following additional subgroup analyses if sufficient data are available in future versions of this review. </p> <p> <ul id="CD013683-list-0010"> <li> <p>Interventions:</p> <ul id="CD013683-list-0011"> <li> <p>different doses of drugs;</p> </li> <li> <p>different combination of interventions; and</p> </li> <li> <p>duration of prophylaxis (e.g. until 30 days after surgery or more).</p> </li> </ul> </li> <li> <p>Participant characteristics:</p> <ul id="CD013683-list-0012"> <li> <p>age (e.g. 15 years to 24 years, 25 years to 64 years and 65 years and over);</p> </li> <li> <p>sex;</p> </li> <li> <p>BMI;</p> </li> <li> <p>race;</p> </li> <li> <p>comorbidities; and</p> </li> <li> <p>presence or absence of non‐alcoholic fatty liver disease (diagnosed either by ultrasonography, CT or biopsy). </p> </li> </ul> </li> <li> <p>Type of bariatric surgery:</p> <ul id="CD013683-list-0013"> <li> <p>gastric bypass, gastric sleeve, duodenal switch, gastric banding, gastric balloon, vagal blocking, aspiration therapy, etc. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD013683-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>We had planned to carry out the following sensitivity analyses, to test whether key methodological factors or decisions affected the main result, grouping by study design (individual, cross‐over or cluster‐randomised), as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013683-bbs2-0039" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Deeks 2019</a>): </p> <p> <ul id="CD013683-list-0014"> <li> <p>exclusion of quasi‐RCTs to determine any impact on the overall results;</p> </li> <li> <p>inclusion of studies with low risk of bias only (considering overall risk of bias of an included study as low if there was no high‐risk judgement in random sequence generation, allocation concealment, incomplete outcome data and selective reporting); </p> </li> <li> <p>examination of fixed‐effect model and random‐effects model meta‐analyses, to explore the differences between the two estimates; </p> </li> <li> <p>exclusion of trials with mixed populations where all participants were included (where at least 50% were of interest) to determine their impact on the primary analyses; and </p> </li> <li> <p>exclusion of studies with missing data that were unobtainable, to determine their impact on the primary analyses. </p> </li> </ul> </p> <p>We had also planned to carry out sensitivity analyses considering cross‐over and cluster‐RCTs. We had planned to investigate the effect of variation in the ICC, acknowledge heterogeneity in the randomisation unit, and perform a sensitivity analysis to investigate the effects of the randomisation unit. We would have presented these results and compared them with the overall findings. </p> </section> <section id="CD013683-sec-0041"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used GRADEpro GDT software (<a href="./references#CD013683-bbs2-0055" title="GRADEpro GDT. Version accessed 31 October 2022. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>) to prepare summary of findings tables with the key information on pharmacological interventions for preventing VTE in participants undergoing bariatric surgery (<a href="./references#CD013683-bbs2-0086" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Schünemann 2019b</a>). We created one table for each treatment comparison for the 'early' time point. We included the following outcomes in each table: </p> <p> <ul id="CD013683-list-0015"> <li> <p>VTE;</p> </li> <li> <p>major bleeding;</p> </li> <li> <p>all‐cause mortality;</p> </li> <li> <p>VTE‐related mortality;</p> </li> <li> <p>PE;</p> </li> <li> <p>DVT; and</p> </li> <li> <p>adverse events (thrombocytopenia).</p> </li> </ul> </p> <p>We used the GRADE approach to rate the certainty of the evidence for each outcome as high, moderate, low, or very low, based on the criteria of risk of bias, inconsistency, indirectness, imprecision, and publication bias (<a href="./references#CD013683-bbs2-0027" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490-4. [PMID: 15205295]">Atkins 2004</a>; <a href="./references#CD013683-bbs2-0085" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Schünemann 2019a</a>). We based the summary of findings tables on methods described in Chapter 11 and 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, and justified any departures from the standard methods (<a href="./references#CD013683-bbs2-0027" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490-4. [PMID: 15205295]">Atkins 2004</a>; <a href="./references#CD013683-bbs2-0085" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Schünemann 2019a</a>; <a href="./references#CD013683-bbs2-0086" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Schünemann 2019b</a>). </p> <section id="CD013683-sec-0042"> <h5 class="title">Reaching conclusions</h5> <p>We based our conclusions only on findings from the quantitative or narrative synthesis of included studies for this review, and we avoided making recommendations for practice. In the <a href="#CD013683-sec-0122">Implications for research</a> section we suggested priorities for future research and outlined the remaining uncertainties in the area. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013683-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013683-sec-0043"></div> <section id="CD013683-sec-0044"> <h3 class="title">Description of studies</h3> <section id="CD013683-sec-0045"> <h4 class="title">Results of the search</h4> <p>We performed database searches in November 2021. After excluding duplicate records, we screened the titles and abstracts of 4982 unique records, excluding 4939 records and retrieving the full‐text articles of 43 potentially eligible records. After the full‐text assessment, we included seven studies (14 reports; <a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a>; <a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a>; <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>). We excluded nine studies (nine reports) with reasons (see <a href="./references#CD013683-sec-0138" title="">Characteristics of excluded studies</a> table). We considered 15 reports to be irrelevant. There are no studies awaiting classification. Five studies (five reports) are ongoing (see <a href="./references#CD013683-sec-0139" title="">Characteristics of ongoing studies</a> table). <a href="#CD013683-fig-0001">Figure 1</a> shows the flow of studies. </p> <div class="figure" id="CD013683-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013683-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013683-sec-0046"> <h4 class="title">Included studies</h4> <p>The seven included studies assessed 1045 participants who underwent bariatric surgery and received an intervention for preventing VTE. All studies analysed prophylactic anticoagulants. We extracted data for four comparisons: </p> <p> <ol id="CD013683-list-0016"> <li> <p>higher‐dose heparin versus standard‐dose heparin (<a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>); </p> </li> <li> <p>heparin versus pentasaccharide (<a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a>); </p> </li> <li> <p>heparin started before surgery versus heparin started after surgery (<a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a>); and </p> </li> <li> <p>combined mechanical and pharmacological prophylaxis versus mechanical prophylaxis alone (<a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a>). </p> </li> </ol> </p> <p>For details of the included studies, see the <a href="./references#CD013683-sec-0137" title="">Characteristics of included studies</a> table. </p> <section id="CD013683-sec-0047"> <h5 class="title">Design</h5> <p>All seven included studies were classified as parallel RCTs, but three did not provide details on the method used for randomisation (<a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>). Six studies had two arms (<a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a>; <a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a>; <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a>) and one study had three arms (<a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>). </p> <p>Although the nature of the intervention allowed for blinding of participants, personnel and outcome assessors, no studies were triple‐blind. <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a> adequately described blinding of personnel and participants but did not describe blinding of outcome assessors. <a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a>, <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a> and <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a> did not adequately describe the blinding methods, and two studies were unblinded (<a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>). <a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a> reported that surgeons and ultrasonographers were blind to the study groups; however, the study authors did not describe any method of blinding participants (we considered participants unblinded for this review) or outcome assessors. </p> </section> <section id="CD013683-sec-0048"> <h5 class="title">Settings</h5> <p>Five studies were performed in a single centre, in Egypt (<a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a>; <a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a>), Iran (<a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>), Greece (<a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>) and the USA (<a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a>). Two other studies were performed as single‐country, multicentre collaborations, in Italy (<a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>) and France (<a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>). </p> </section> <section id="CD013683-sec-0049"> <h5 class="title">Participants</h5> <p>The studies randomised 1069 participants, of whom 1045 were effectively analysed. The reason for exclusion of participants after randomisation varied from withdrawn concealment, refusing surgery, inclusion criteria not met, or logistical problems (<a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>). The mean age ranged from 33.7 (standard deviation (SD) 9.7) years to 41.8 (SD 9.4) years. Although all studies considered both sexes for enrolment, the number of female participants was considerably higher, with a total male to female ratio of 173:896. </p> </section> <section id="CD013683-sec-0050"> <h5 class="title">Sample size</h5> <p>The sample size ranged from 60 participants in <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a> to 258 participants in <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>. Only one study enroled fewer than 100 participants (<a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>). </p> </section> <section id="CD013683-sec-0051"> <h5 class="title">Funding</h5> <p><a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a> declared that "there are no funds for this study as it was held in a university hospital". <a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a> declared that "the authors received no financial support for the research, authorship, and/or publication of this article". <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a> declared their study was funded by the Tehran University of Medical Sciences and Health Services. <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a> and <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a> stated that they were funded by pharmaceutical companies (Alfa Wasserman for <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a> and GlaxoSmithKline for <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a>), but that the companies did not interfere in the study design, results or reports. <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a> reported that the study was partially funded by a pharmaceutical company (Sanofi‐Aventis) and partially funded by institutional grants, but that the funders did not have any role in their study design, conduction, analysis or report. <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a> did not report their funding source. </p> </section> <section id="CD013683-sec-0052"> <h5 class="title">Conflicts of interest</h5> <p>The authors of <a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a>, <a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a>, <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>, <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>, <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a> and <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a> declared no conflict of interest. <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a> made no statement about conflict of interest. </p> </section> <section id="CD013683-sec-0053"> <h5 class="title">Interventions</h5> <p>Four studies compared different dose regimens of the same heparin. <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a> analysed UFH 5000 IU three times per day versus UFH 5000 IU twice per day. <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a> compared the LMWH parnaparin 6400 IU per day to parnaparin 4250 IU per day, started 12 hours preoperatively and administered for a mean period of 9 (SD 2) days. <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a> compared nadroparin (LMWH) 9500 IU per day to nadroparin 5700 IU per day, started preoperatively then administered once daily postoperatively until discharge. <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a> compared enoxaparin (LMWH) at three different doses (4000 IU twice per day and once per day, and 6000 IU once per day). </p> <p><a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a> compared enoxaparin (LMWH) 40 mg twice a day during hospitalisation, starting on call to the operating room versus fondaparinux sodium (pentasaccharide) 5 mg once daily during hospitalisation, starting six hours following surgery. </p> <p><a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a> analysed the administration of enoxaparin (LMWH) 1 mg/kg/day (with a maximum dose of 120 mg per day), started 12 hours before surgery and administered at the same dose after surgery until the 15th postoperative day, versus the same drug at the same dose but administered only after surgery until the 15th postoperative day. </p> <p><a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a> compared enoxaparin (LMWH) 40 mg administered 12 hours before surgery and every 24 hours after surgery for two weeks, combined with mechanical interventions (elastic stocking and early ambulation) versus mechanical interventions alone (elastic stocking and early ambulation). </p> <p>All participants in <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>, <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a>, and <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a> received mechanical interventions (e.g. compression stocking, early ambulation or sequential compression devices). <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a> reported that most (but not all) participants received at least one mechanical intervention. <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a> did not report on the use of mechanical interventions. <a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a> reported that "patients were encouraged to ambulate a few hours postoperatively and to continue mobility on a regular basis when discharged home", but provided no data on the effective adherence of participants to these recommendations. <a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a> did not report any other mechanical intervention. </p> <p>No studies reported the level of experience of the person carrying out the procedure.</p> </section> <section id="CD013683-sec-0054"> <h5 class="title">Outcomes</h5> <p>The seven studies measured similar outcomes, and we were able to extract data for all outcomes of this review except QoL. The most frequent outcome measures were VTE, major bleeding, all‐cause mortality and VTE‐related mortality. Studies assessed these outcomes at different time points, ranging from seven to 180 days after the start of the intervention. Four studies evaluated data up to 90 days after the start of the intervention (i.e. the cut‐off for our pre‐established early time point; <a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a>; <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>). <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a> reported data up to two weeks, without explaining why the follow‐up differed from that proposed in their protocol (two years). We tried to obtain clarification by email without success. <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a> provided data for long‐term follow‐up (up to 180 days after the intervention). <a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a> presented data for at least four weeks' follow‐up; participants who experienced a VTE event had their follow‐up increased to six months as they had to continue anticoagulation treatment. </p> <section id="CD013683-sec-0055"> <h6 class="title">Primary outcomes</h6> <p>All studies provided data on VTE and major bleeding.</p> </section> <section id="CD013683-sec-0056"> <h6 class="title">Secondary outcomes</h6> <p>All studies reported all‐cause mortality, VTE‐related mortality and DVT until the end of the study period. </p> <p>Only <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>, <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a> and <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a> provided data on PE and adverse events. <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a> and <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a> reported only thrombocytopenia adverse events, and <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a> reported thrombocytopenia and other adverse events (atrial fibrillation, rash and nausea and vomiting). <a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a>, <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>, <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a> and <a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a> made no mention of adverse events or PE. </p> <p>No studies provided data on QoL.</p> </section> </section> </section> <section id="CD013683-sec-0057"> <h4 class="title">Excluded studies</h4> <p>We excluded eight studies due to ineligible study design (non‐randomised, cohort or retrospective studies; <a href="./references#CD013683-bbs2-0008" title="BirkmeyerNJ , FinksJF , CarlinAM , ChengelisDL , KrauseKR , HawasliAA , et al. Comparative effectiveness of unfractionated and low-molecular-weight heparin for prevention of venous thromboembolism following bariatric surgery. Archives of Surgery2012;147(11):994-8. [DOI: 10.1001/archsurg.2012.2298]">Birkmeyer 2012</a>; <a href="./references#CD013683-bbs2-0009" title="Borkgren-OkonekMJ , HartRW , PantanoJE , RantisPC , GuskePJ , KaneJM , et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surgery for Obesity and Related Diseases2008;4(5):625-31. [DOI: 10.1016/j.soard.2007.11.010]">Borkgren‐Okonek 2008</a>; <a href="./references#CD013683-bbs2-0010" title="GoslanCJ , BarettaGA , deSouzaHG , OrsiBZ , ZanoniEC , LopesMA , et al. Deep venous thrombosis prevention in bariatric surgery: comparative study of different doses of low weight molecular heparin [Profilaxia da trombose venosa profunda em cirurgia bariátrica: estudo comparativo com doses diferentes de heparina de baixo peso molecular]. Jornal Vascular Brasileiro2018;17(1):26-33. [DOI: 10.1590/1677-5449.008417]">Goslan 2018</a>; <a href="./references#CD013683-bbs2-0011" title="KushnirM , GaliR , AlexanderM , BillettHH . Efficacy and safety of direct oral factor Xa inhibitors in patients after bariatric surgery. Blood2019;134(Suppl 1):2439. ">Kushnir 2019</a>; <a href="./references#CD013683-bbs2-0012" title="MageeC , BarryJ , AhmedJ , JavedS , MacadamR , KerriganD . Comparison of dalteparin and enoxaparin in preventing venous thromboembolism following laparoscopic bariatric surgery. Obesity Surgery2009;19:1000. [DOI: 10.1007/s11695-009-9904-9]">Magee 2009</a>; <a href="./references#CD013683-bbs2-0014" title="RaftopoulosI , MartindaleC , CroninA , SteinbergJ . The effect of extended post-discharge chemical thromboprophylaxis on venous thromboembolism rates after bariatric surgery: a prospective comparison trial. Surgical Endoscopy and Other Interventional Techniques2008;22(11):2384-91. [DOI: 10.1007/s00464-008-0031-9]">Raftopoulos 2008</a>; <a href="./references#CD013683-bbs2-0015" title="ScholtenDJ , HoedemaRM , ScholtenSE . A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obesity Surgery2002;12(1):19-24. [DOI: 10.1381/096089202321144522]">Scholten 2002</a>; <a href="./references#CD013683-bbs2-0016" title="SimoneEP , MadanAK , TichanskyDS , KuhlDA , LeeMD . Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. Surgical Endoscopy and Other Interventional Techniques2008;22(11):2392-5. [DOI: 10.1007/s00464-008-9997-6]">Simone 2008</a>), and one study due to wrong population (people undergoing plastic or reconstructive surgery; <a href="./references#CD013683-bbs2-0013" title="PannucciCJ , FlemingKI , BertolacciniC , AgarwalJ , RockwellWB , MendenhallSD , et al. Optimal dosing of prophylactic enoxaparin after surgical procedures: results of the double-blind, randomized, controlled fixed or variable enoxaparin (FIVE) trial. Plastic and Reconstructive Surgery2021;147(4):947-58. ">Pannucci 2021</a>). See <a href="./references#CD013683-sec-0138" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD013683-sec-0058"> <h4 class="title">Ongoing studies</h4> <p>We identified five ongoing studies, evaluating at least one of the following interventions for preventing VTE in people undergoing bariatric surgery: </p> <p> <ul id="CD013683-list-0017"> <li> <p>heparin (UFH or LMWH; <a href="./references#CD013683-bbs2-0017" title="BalibreaJM , CorcellesR , MorenoP , MansE , SabenchF , VilallongaR , et al. Apixaban versus enoxaparin for postoperative thromboprophylaxis after sleeve gastrectomy. A proposal for randomized controlled trial. Obesity Surgery2017;27(1 Suppl 1):479-80. [DOI: 10.1007/s11695-017-2774-7]">Balibrea 2017</a>; <a href="./references#CD013683-bbs2-0018" title="NCT01970202. Anti Xa levels under two different regimens of enoxaparin VTE prophylaxis after sleeve gastrectomy for morbid obesity. clinicaltrials.gov/ct2/show/NCT01970202 (first received 14 October 2013). ">NCT01970202</a>; <a href="./references#CD013683-bbs2-0019" title="NCT02128178. Laparoscopic bariatric surgery: two regimens of venous thromboprophylaxis: prospective randomized study. clinicaltrials.gov/show/NCT02128178 (first received 22 April 2014). ">NCT02128178</a>; <a href="./references#CD013683-bbs2-0021" title="TCTR20201016001. A randomized controlled trial comparison of enoxaparin 40 mg versus 60 mg dosage for venous thromboembolism prophylaxis in bariatric surgery. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20201016001 (first received 16 October 2020). ">TCTR20201016001</a>); or </p> </li> <li> <p>DOACs, factor Xa inhibitors and direct thrombin inhibitors (<a href="./references#CD013683-bbs2-0017" title="BalibreaJM , CorcellesR , MorenoP , MansE , SabenchF , VilallongaR , et al. Apixaban versus enoxaparin for postoperative thromboprophylaxis after sleeve gastrectomy. A proposal for randomized controlled trial. Obesity Surgery2017;27(1 Suppl 1):479-80. [DOI: 10.1007/s11695-017-2774-7]">Balibrea 2017</a>; <a href="./references#CD013683-bbs2-0020" title="NCT03522259. Rivaroxaban as thrombosis prophylaxis in bariatric surgery (BARIVA). clinicaltrials.gov/ct2/show/NCT03522259 (first received 30 April 2018). ">NCT03522259</a>). </p> </li> </ul> </p> <p>For our primary outcomes, <a href="./references#CD013683-bbs2-0017" title="BalibreaJM , CorcellesR , MorenoP , MansE , SabenchF , VilallongaR , et al. Apixaban versus enoxaparin for postoperative thromboprophylaxis after sleeve gastrectomy. A proposal for randomized controlled trial. Obesity Surgery2017;27(1 Suppl 1):479-80. [DOI: 10.1007/s11695-017-2774-7]">Balibrea 2017</a>, <a href="./references#CD013683-bbs2-0019" title="NCT02128178. Laparoscopic bariatric surgery: two regimens of venous thromboprophylaxis: prospective randomized study. clinicaltrials.gov/show/NCT02128178 (first received 22 April 2014). ">NCT02128178</a>, and <a href="./references#CD013683-bbs2-0020" title="NCT03522259. Rivaroxaban as thrombosis prophylaxis in bariatric surgery (BARIVA). clinicaltrials.gov/ct2/show/NCT03522259 (first received 30 April 2018). ">NCT03522259</a> plan to provide data on VTE, and <a href="./references#CD013683-bbs2-0017" title="BalibreaJM , CorcellesR , MorenoP , MansE , SabenchF , VilallongaR , et al. Apixaban versus enoxaparin for postoperative thromboprophylaxis after sleeve gastrectomy. A proposal for randomized controlled trial. Obesity Surgery2017;27(1 Suppl 1):479-80. [DOI: 10.1007/s11695-017-2774-7]">Balibrea 2017</a> and <a href="./references#CD013683-bbs2-0019" title="NCT02128178. Laparoscopic bariatric surgery: two regimens of venous thromboprophylaxis: prospective randomized study. clinicaltrials.gov/show/NCT02128178 (first received 22 April 2014). ">NCT02128178</a> plan to provide data on major bleeding. For our secondary outcomes, only <a href="./references#CD013683-bbs2-0020" title="NCT03522259. Rivaroxaban as thrombosis prophylaxis in bariatric surgery (BARIVA). clinicaltrials.gov/ct2/show/NCT03522259 (first received 30 April 2018). ">NCT03522259</a> plans to report all‐cause mortality, and only <a href="./references#CD013683-bbs2-0017" title="BalibreaJM , CorcellesR , MorenoP , MansE , SabenchF , VilallongaR , et al. Apixaban versus enoxaparin for postoperative thromboprophylaxis after sleeve gastrectomy. A proposal for randomized controlled trial. Obesity Surgery2017;27(1 Suppl 1):479-80. [DOI: 10.1007/s11695-017-2774-7]">Balibrea 2017</a> plans to report adverse events. No ongoing studies plan to report VTE‐related mortality, DVT and PE (separately) or QoL. <a href="./references#CD013683-bbs2-0018" title="NCT01970202. Anti Xa levels under two different regimens of enoxaparin VTE prophylaxis after sleeve gastrectomy for morbid obesity. clinicaltrials.gov/ct2/show/NCT01970202 (first received 14 October 2013). ">NCT01970202</a> plans to report laboratory outcomes but included none of the outcomes relevant to this review in their planning. <a href="./references#CD013683-bbs2-0021" title="TCTR20201016001. A randomized controlled trial comparison of enoxaparin 40 mg versus 60 mg dosage for venous thromboembolism prophylaxis in bariatric surgery. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20201016001 (first received 16 October 2020). ">TCTR20201016001</a> plans to report anti‐Xa levels but has made no mention of any other prespecified outcomes. </p> <p>We tried to contact trial authors, and we searched by the trial registration number and title on all databases of interest, but we identified no additional data for any of these ongoing studies. </p> </section> </section> <section id="CD013683-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>We provided justifications for our risk of bias judgements in the <a href="./references#CD013683-sec-0137" title="">Characteristics of included studies</a> table. <a href="#CD013683-fig-0002">Figure 2</a> and <a href="#CD013683-fig-0003">Figure 3</a> summarise the review authors' judgements about each risk of bias item in graphical format. </p> <div class="figure" id="CD013683-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013683-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013683-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013683-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>We also judged the overall risk of bias as described in the <a href="#CD013683-sec-0040">Sensitivity analysis</a> section. We considered <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a> to have high overall risk of bias and all other studies to have low overall risk of bias (<a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a>; <a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a>; <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>). </p> <section id="CD013683-sec-0060"> <h4 class="title">Allocation</h4> <section id="CD013683-sec-0061"> <h5 class="title">Random sequence generation</h5> <p>We considered four studies at low risk of bias related to random sequence generation (<a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a>; <a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a>; <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a>), and the remaining three at unclear risk as they did not describe the randomisation method (<a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>). </p> </section> <section id="CD013683-sec-0062"> <h5 class="title">Allocation concealment</h5> <p>We judged <a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a> and <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a> at low risk of bias related to allocation concealment, and the remaining five studies at unclear risk due to lack of information (<a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a>; <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>). </p> </section> </section> <section id="CD013683-sec-0063"> <h4 class="title">Blinding</h4> <section id="CD013683-sec-0064"> <h5 class="title">Blinding of participants and personnel</h5> <p>We considered only <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a> at low risk of performance bias. Three studies provided no information about the blinding of participants, so we considered them at unclear risk (<a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a>; <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>). We judged the remaining three studies at high risk of bias because they did not blind participants (<a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a>; <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>). </p> </section> <section id="CD013683-sec-0065"> <h5 class="title">Blinding of outcome assessment</h5> <p>We judged four studies at unclear risk of detection bias due to lack of information (<a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a>; <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a>), two studies at high risk because they did not blind outcome assessors (<a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>), and only <a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a> at low risk. </p> </section> </section> <section id="CD013683-sec-0066"> <h4 class="title">Incomplete outcome data</h4> <p>We considered all studies at low risk of attrition bias (<a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a>; <a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a>; <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>). </p> </section> <section id="CD013683-sec-0067"> <h4 class="title">Selective reporting</h4> <p>We considered six studies at low risk of reporting bias (<a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a>; <a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a>; <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>), and <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a> at high risk because it excluded 21/198 (10.6%) participants from the assessment of VTE and DVT occurrence (in fact, two more participants were not included in the analysis of VTE and DVT, but <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a> did not mention the reason for this loss of data). </p> </section> <section id="CD013683-sec-0068"> <h4 class="title">Other potential sources of bias</h4> <p>We judged six studies at low risk of other bias (<a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a>; <a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a>; <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>), and <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a> at high risk because the prespecified outcomes differed from those included in the final report. </p> </section> </section> <section id="CD013683-sec-0069"> <h3 class="title" id="CD013683-sec-0069">Effects of interventions</h3> <p>See: <a href="./full#CD013683-tbl-0001"><b>Summary of findings 1</b> Higher‐dose heparin compared to standard‐dose heparin for preventing venous thromboembolism in people undergoing bariatric surgery</a>; <a href="./full#CD013683-tbl-0002"><b>Summary of findings 2</b> Heparin compared to pentasaccharide for preventing venous thromboembolism in people undergoing bariatric surgery</a>; <a href="./full#CD013683-tbl-0003"><b>Summary of findings 3</b> Heparin started before compared to after the surgical procedure for preventing venous thromboembolism in people undergoing bariatric surgery</a>; <a href="./full#CD013683-tbl-0004"><b>Summary of findings 4</b> Combined mechanical and pharmacological prophylaxis compared to mechanical prophylaxis alone for preventing venous thromboembolism in people undergoing bariatric surgery</a> </p> <section id="CD013683-sec-0070"> <h4 class="title">Higher‐dose heparin versus standard‐dose heparin</h4> <p>Four studies compared higher‐dose to standard‐dose heparin in people undergoing bariatric surgery, reporting outcomes of interest for this review with a follow‐up of 90 days or less (<a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>). </p> <section id="CD013683-sec-0071"> <h5 class="title">Primary outcomes</h5> <section id="CD013683-sec-0072"> <h6 class="title">Venous thromboembolism</h6> <p>Only <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a> reported VTE events. The other three studies reported no events in either group (<a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>). Higher‐dose heparin may result in little or no difference in VTE compared to standard‐dose heparin in people undergoing bariatric surgery (RR 0.55, 95% CI 0.05 to 5.99; 4 studies, 597 participants; low‐certainty evidence; <a href="./references#CD013683-fig-0004" title="">Analysis 1.1</a>). We downgraded the certainty of the evidence by one level due to the high risk of performance and detection bias, and by one level due to imprecision (few events and CI consistent with possible benefit and possible harm). The test for subgroup differences and the sensitivity analysis was not applicable because only <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a> reported events. </p> </section> <section id="CD013683-sec-0073"> <h6 class="title">Major bleeding</h6> <p>All four studies reported major bleeding with a follow‐up of 10 to 90 days (<a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>). Higher‐dose heparin may result in little or no difference in major bleeding compared to standard‐dose heparin in people undergoing bariatric surgery (RR 1.19, 95% CI 0.48 to 2.96; I<sup>2</sup> = 8%; 4 studies, 597 participants; low‐certainty evidence; <a href="./references#CD013683-fig-0005" title="">Analysis 1.2</a>). We downgraded the certainty of the evidence by one level due to the high risk of performance and detection bias, and one level due to imprecision (few events and CI consistent with possible benefit and possible harm). The test for subgroup differences suggested that the type of heparin had no modifying effect on major bleeding (I<sup>2</sup> = 0%, Chi<sup>2</sup> = 0.77, df = 1 (P = 0.38)). The sensitivity analysis was not applicable because we judged all studies as having low overall risk of bias. </p> </section> </section> <section id="CD013683-sec-0074"> <h5 class="title">Secondary outcomes</h5> <section id="CD013683-sec-0075"> <h6 class="title">All‐cause mortality</h6> <p>All four studies reported no deaths in either group during a follow‐up of 10 to 90 days (<a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>). The effect of higher‐dose heparin on all‐cause mortality compared to standard‐dose heparins from 10 to 90 days was not estimable (no events in either group; 4 studies, 597 participants; low‐certainty evidence; <a href="./references#CD013683-fig-0006" title="">Analysis 1.3</a>). We downgraded the certainty of the evidence by two levels due to imprecision (no events). The test for subgroup differences and the sensitivity analysis were not applicable because there were no events. </p> </section> <section id="CD013683-sec-0076"> <h6 class="title">Venous thromboembolism‐related mortality</h6> <p>All four studies reported no deaths in either group during a follow‐up of 10 to 90 days (<a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>). The effect of higher‐dose heparin on VTE‐related mortality compared to standard‐dose heparin from 10 to 90 days was not estimable (no events in either group; 4 studies, 597 participants; low‐certainty evidence; <a href="./references#CD013683-fig-0007" title="">Analysis 1.4</a>). We downgraded the certainty of the evidence by two levels due to imprecision (no events). The test for subgroup differences and the sensitivity analysis were not applicable because there were no events. </p> </section> <section id="CD013683-sec-0077"> <h6 class="title">Pulmonary embolism</h6> <p><a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a> and <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a> assessed PE with a follow‐up of 90 days or less. Both studies used LMWH. <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a> reported no events in either group. <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a> reported one PE event in the standard‐dose heparin group. The evidence on PE is uncertain for people undergoing bariatric surgery (RR 0.37, 95% CI 0.02 to 8.92; 2 studies, 310 participants; very low‐certainty evidence; <a href="./references#CD013683-fig-0008" title="">Analysis 1.5</a>). We downgraded the certainty of the evidence by one level due to the high risk of performance and detection bias, and by two levels due to imprecision (very large CI of the absolute difference and few events). The test for subgroup differences and the sensitivity analysis were not applicable because only <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a> reported events. </p> </section> <section id="CD013683-sec-0078"> <h6 class="title">Deep vein thrombosis</h6> <p>All four studies assessed DVT with a follow‐up of 10 to 90 days (<a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>), but only <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a> reported events (one case of DVT in each group). The evidence on DVT is uncertain for people undergoing bariatric surgery (RR 1.10, 95% CI 0.07 to 17.40; 4 studies, 597 participants; very low‐certainty evidence; <a href="./references#CD013683-fig-0009" title="">Analysis 1.6</a>). We downgraded the certainty of the evidence by one level due to the high risk of performance and detection bias, and by two levels due to imprecision (very large CI of the absolute difference and few events). The test for subgroup differences and the sensitivity analysis were not applicable because only <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a> reported events. </p> </section> <section id="CD013683-sec-0079"> <h6 class="title">Adverse events</h6> <p>In this comparison, the only reported adverse event was thrombocytopenia. <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a> and <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a> assessed thrombocytopenia with a follow‐up of 90 days or less. <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a> reported no events in either group. <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a> reported one event in each group. Both studies used LMWH. The evidence on adverse events (thrombocytopenia) is uncertain for people undergoing bariatric surgery (RR 1.10, 95% CI 0.07 to 17.40; 2 studies, 310 participants; very low‐certainty evidence; <a href="./references#CD013683-fig-0010" title="">Analysis 1.7</a>). We downgraded the certainty of the evidence by one level due to the high risk of performance and detection bias, and by two levels due to imprecision (very large CI of the absolute difference and few events). The test for subgroup differences and the sensitivity analysis were not applicable because only <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a> reported events. </p> </section> <section id="CD013683-sec-0080"> <h6 class="title">Quality of life</h6> <p>There were no data for QoL.</p> </section> </section> </section> <section id="CD013683-sec-0081"> <h4 class="title">Heparin versus pentasaccharide</h4> <p>Only <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a> compared LMWH versus a pentasaccharide in people undergoing bariatric surgery, reporting outcomes of interest for this review with a follow‐up of up to 14 days. The test for subgroup differences and sensitivity analysis were not applicable for any outcome, as there was only one study in this comparison. </p> <section id="CD013683-sec-0082"> <h5 class="title">Primary outcomes</h5> <section id="CD013683-sec-0083"> <h6 class="title">Venous thromboembolism</h6> <p>Heparin may result in little or no difference in risk of VTE compared to pentasaccharide in people undergoing bariatric surgery (RR 0.83, 95% CI 0.19 to 3.61; 175 participants; low‐certainty evidence; <a href="./references#CD013683-fig-0011" title="">Analysis 2.1</a>). We downgraded the certainty of the evidence by one level due to the high risk of reporting and other bias, and by one level due to imprecision (few participants, and 95% CI consistent with possible benefit and possible harm). </p> </section> <section id="CD013683-sec-0084"> <h6 class="title">Major bleeding</h6> <p>The evidence on major bleeding is uncertain (RR 1.70, 95% CI 0.42 to 6.92; 198 participants; very low‐certainty evidence; <a href="./references#CD013683-fig-0012" title="">Analysis 2.2</a>). We downgraded the certainty of the evidence by one level due to the high risk of reporting and other bias, and by two levels due to imprecision (few events and very large CI of absolute difference). </p> </section> </section> <section id="CD013683-sec-0085"> <h5 class="title">Secondary outcomes</h5> <section id="CD013683-sec-0086"> <h6 class="title">All‐cause mortality</h6> <p>The effect of heparin compared to pentasaccharide up to 14 days on all‐cause mortality was not estimable (no events in either group; 198 participants; very low‐certainty evidence; <a href="./references#CD013683-fig-0013" title="">Analysis 2.3</a>). We downgraded the certainty of the evidence by one level due to the high risk of reporting and other bias, and by two levels due to imprecision (no events). </p> </section> <section id="CD013683-sec-0087"> <h6 class="title">Venous thromboembolism‐related mortality</h6> <p>The effect of heparin compared to pentasaccharide up to 14 days on VTE‐related mortality was not estimable (no events in either group; 198 participants; very low‐certainty evidence; <a href="./references#CD013683-fig-0014" title="">Analysis 2.4</a>). We downgraded the certainty of the evidence by one level due to the high risk of reporting and other bias, and by two levels due to imprecision (no events). </p> </section> <section id="CD013683-sec-0088"> <h6 class="title">Pulmonary embolism</h6> <p>The effect of heparin compared to pentasaccharide up to 14 days on PE was not estimable (no events in either group; 198 participants; very low‐certainty evidence; <a href="./references#CD013683-fig-0015" title="">Analysis 2.5</a>). We downgraded the certainty of the evidence by one level due to the high risk of reporting and other bias, and by two levels due to imprecision (no events). </p> </section> <section id="CD013683-sec-0089"> <h6 class="title">Deep vein thrombosis</h6> <p>Heparin may result in little or no difference in DVT compared to pentasaccharide in people undergoing bariatric surgery (RR 0.83, 95% CI 0.19 to 3.61; 175 participants; low‐certainty evidence; <a href="./references#CD013683-fig-0016" title="">Analysis 2.6</a>). We downgraded the certainty of the evidence by one level due to the high risk of reporting and other bias, and by one level due to imprecision (few participants and 95% CI consistent with possible benefit and possible harm). </p> </section> <section id="CD013683-sec-0090"> <h6 class="title">Adverse events</h6> <p><a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a> reported the adverse events thrombocytopenia, atrial fibrillation, rash, and nausea and vomiting. </p> <p>The evidence on adverse events (thrombocytopenia) is uncertain for people undergoing bariatric surgery (RR 0.34, 95% CI 0.01 to 8.25; 198 participants; very low‐certainty evidence; <a href="./references#CD013683-fig-0017" title="">Analysis 2.7</a>). We downgraded the certainty of the evidence by one level due to the high risk of reporting and other bias, and by two levels due to imprecision (few events and very large CI of absolute difference). </p> <p>The evidence on adverse events (atrial fibrillation) is uncertain for people undergoing bariatric surgery (RR 2.04, 95% CI 0.19 to 22.14; 198 participants; very low‐certainty evidence; <a href="./references#CD013683-fig-0018" title="">Analysis 2.8</a>). We downgraded the certainty of the evidence by one level due to the high risk of reporting and other bias, and by two levels due to imprecision (few events and very large CI of absolute difference). </p> <p>The evidence on adverse events (rash) is uncertain for people undergoing bariatric surgery (RR 1.02, 95% CI 0.06 to 16.09; 198 participants; very low‐certainty evidence; <a href="./references#CD013683-fig-0019" title="">Analysis 2.9</a>). We downgraded the certainty of the evidence by one level due to the high risk of reporting and other bias, and by two levels due to imprecision (few events and very large CI of absolute difference). </p> <p>The evidence on adverse events (nausea and vomiting) is uncertain for people undergoing bariatric surgery (RR 1.02, 95% CI 0.15 to 7.10; 198 participants; very low‐certainty evidence; <a href="./references#CD013683-fig-0020" title="">Analysis 2.10</a>). We downgraded the certainty of the evidence by one level due to the high risk of reporting and other bias, and by two levels due to imprecision (few events and very large CI of the absolute difference). </p> </section> <section id="CD013683-sec-0091"> <h6 class="title">Quality of life</h6> <p>There were no data for QoL.</p> </section> </section> </section> <section id="CD013683-sec-0092"> <h4 class="title">Heparin started before versus after the surgical procedure</h4> <p>Only <a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a> compared LMWH starting before versus after the bariatric surgery, reporting outcomes of interest for this review with a follow‐up of 15 days. The test for subgroup differences and sensitivity analysis were not applicable for any outcome, as there was only one study in this comparison. </p> <section id="CD013683-sec-0093"> <h5 class="title">Primary outcomes</h5> <section id="CD013683-sec-0094"> <h6 class="title">Venous thromboembolism</h6> <p>Starting heparin before the surgical procedure may result in little or no difference in VTE compared to starting heparin after the procedure in people undergoing bariatric surgery (RR 0.11, 95% CI 0.01 to 2.01; 100 participants; low‐certainty evidence; <a href="./references#CD013683-fig-0021" title="">Analysis 3.1</a>). We downgraded the certainty of the evidence by one level due to the high risk of performance bias, and by one level due to imprecision (few participants and 95% CI consistent with possible benefit and possible harm). </p> </section> <section id="CD013683-sec-0095"> <h6 class="title">Major bleeding</h6> <p>The evidence on major bleeding is uncertain for people undergoing bariatric surgery (RR 3.00, 95% CI 0.13 to 71.92; 100 participants; very low‐certainty evidence; <a href="./references#CD013683-fig-0022" title="">Analysis 3.2</a>). We downgraded the certainty of the evidence by one level due to high performance bias, and by two levels due to imprecision (few events, few participants and very large CI). </p> </section> </section> <section id="CD013683-sec-0096"> <h5 class="title">Secondary outcomes</h5> <section id="CD013683-sec-0097"> <h6 class="title">All‐cause mortality</h6> <p>The effect of starting heparin before versus after the surgical procedure on all‐cause mortality at 15 days was not estimable (no events in either group; 100 participants; very low‐certainty evidence; <a href="./references#CD013683-fig-0023" title="">Analysis 3.3</a>). We downgraded the certainty of the evidence by one level due to high performance bias, and by two levels due to imprecision (no events and few participants). </p> </section> <section id="CD013683-sec-0098"> <h6 class="title">Venous thromboembolism‐related mortality</h6> <p>The effect of starting heparin before versus after the surgical procedure on VTE‐related mortality at 15 days was not estimable (no events in either group; 100 participants; very low‐certainty evidence; <a href="./references#CD013683-fig-0024" title="">Analysis 3.4</a>). We downgraded the certainty of the evidence by one level due to high performance bias, and by two levels due to imprecision (no events and few participants). </p> </section> <section id="CD013683-sec-0099"> <h6 class="title">Pulmonary embolism</h6> <p>There were no data for PE.</p> </section> <section id="CD013683-sec-0100"> <h6 class="title">Deep vein thrombosis</h6> <p>Starting heparin before the surgical procedure may result in little or no difference in DVT compared with starting heparin after the procedure in people undergoing bariatric surgery (RR 0.11, 95% CI 0.01 to 2.01; 100 participants; low‐certainty evidence; <a href="./references#CD013683-fig-0025" title="">Analysis 3.5</a>). We downgraded the certainty of the evidence by one level due to high risk of performance bias, and by one level due to imprecision (few events and 95% CI consistent with possible benefit and possible harm). </p> </section> <section id="CD013683-sec-0101"> <h6 class="title">Adverse events</h6> <p>There were no data for adverse events.</p> </section> <section id="CD013683-sec-0102"> <h6 class="title">Quality of life</h6> <p>There were no data for QoL.</p> </section> </section> </section> <section id="CD013683-sec-0103"> <h4 class="title">Combined mechanical and pharmacological prophylaxis versus mechanical prophylaxis alone </h4> <p>Only <a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a> compared LMWH 40 mg started 12 hours before and administered every 24 hours after surgery, combined with elastic stockings and early ambulation, versus elastic stockings and early ambulation alone. The study reported outcomes of interest for this review with a follow‐up of four weeks. The test for subgroup differences and sensitivity analysis were not applicable for any outcome, as there was only one study in this comparison. </p> <section id="CD013683-sec-0104"> <h5 class="title">Primary outcomes</h5> <section id="CD013683-sec-0105"> <h6 class="title">Venous thromboembolism</h6> <p>Combined mechanical and pharmacological prophylaxis may reduce the incidence of VTE compared to mechanical prophylaxis alone in people undergoing bariatric surgery within four weeks (RR 0.05, 95% CI 0.00 to 0.89; NNTB 9; 150 participants; low‐certainty evidence; <a href="./references#CD013683-fig-0026" title="">Analysis 4.1</a>). We downgraded the certainty of the evidence by two levels due to imprecision (few events and small sample size). </p> </section> <section id="CD013683-sec-0106"> <h6 class="title">Major bleeding</h6> <p>The effect of combined mechanical and pharmacological prophylaxis compared to mechanical prophylaxis alone within four weeks on major bleeding was not estimable (no events in either group; 150 participants; low‐certainty evidence; <a href="./references#CD013683-fig-0027" title="">Analysis 4.2</a>). We downgraded the certainty of the evidence by two levels due to imprecision (no events). </p> </section> </section> <section id="CD013683-sec-0107"> <h5 class="title">Secondary outcomes</h5> <section id="CD013683-sec-0108"> <h6 class="title">All‐cause mortality</h6> <p>The effect of combined mechanical and pharmacological prophylaxis compared to mechanical prophylaxis alone within four weeks on all‐cause mortality was not estimable (no events in either group; 150 participants; low‐certainty evidence; <a href="./references#CD013683-fig-0028" title="">Analysis 4.3</a>). We downgraded the certainty of the evidence by two levels due to imprecision (no events). </p> </section> <section id="CD013683-sec-0109"> <h6 class="title">Venous thromboembolism‐related mortality</h6> <p>The effect of combined mechanical and pharmacological prophylaxis compared to mechanical prophylaxis alone within four weeks on VTE‐related mortality was not estimable (no events in either group; 150 participants; low‐certainty evidence; <a href="./references#CD013683-fig-0029" title="">Analysis 4.4</a>). We downgraded the certainty of the evidence by two levels due to imprecision (no events). </p> </section> <section id="CD013683-sec-0110"> <h6 class="title">Pulmonary embolism</h6> <p>There were no data for PE.</p> </section> <section id="CD013683-sec-0111"> <h6 class="title">Deep vein thrombosis</h6> <p>Combined mechanical and pharmacological prophylaxis may reduce the incidence of DVT compared to mechanical prophylaxis alone in people undergoing bariatric surgery (RR 0.05, 95% CI 0.00 to 0.89; 150 participants; low‐certainty evidence; <a href="./references#CD013683-fig-0026" title="">Analysis 4.1</a>). We downgraded the certainty of the evidence by two levels due to imprecision (few events and small sample size). </p> </section> <section id="CD013683-sec-0112"> <h6 class="title">Adverse events</h6> <p>There were no data for adverse events.</p> </section> <section id="CD013683-sec-0113"> <h6 class="title">Quality of life</h6> <p>There were no data for QoL.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013683-sec-0114" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013683-sec-0114"></div> <section id="CD013683-sec-0115"> <h3 class="title" id="CD013683-sec-0115">Summary of main results</h3> <p>We included seven RCTs with 1045 participants. The studies contributed to four comparisons in this review: </p> <p> <ol id="CD013683-list-0018"> <li> <p>higher‐dose heparin versus standard‐dose heparin;</p> </li> <li> <p>heparin versus a pentasaccharide;</p> </li> <li> <p>heparin started before versus after the surgical procedure; and</p> </li> <li> <p>combined mechanical and pharmacological prophylaxis versus mechanical prophylaxis alone. </p> </li> </ol> </p> <p>Six studies analysed only early time points, with follow‐up between seven and 90 days (which meets our protocol expectation). Only one study analysed participants 180 days after the intervention. </p> <p>We found four RCTs (597 participants) that compared higher‐dose versus standard‐dose heparin. One of these studies (139 participants) used UFH and the remaining three (458 participants) used LMWH. Higher‐dose heparin may result in little or no difference in VTE and major bleeding compared to standard‐dose heparin in people undergoing bariatric surgery. The effect of higher‐dose heparin on all‐cause mortality and VTE‐related mortality compared to standard‐dose heparin was not estimable, as the studies reported no events. The evidence on PE, DVT and adverse events (thrombocytopenia) is uncertain. </p> <p>One study with 198 participants compared heparin to a pentasaccharide. Heparin compared to pentasaccharide in people undergoing bariatric surgery may result in little or no difference in VTE or DVT. The effect on all‐cause and VTE‐related mortality was not estimable, as the study reported no events. The evidence on major bleeding, PE and adverse events (thrombocytopenia, atrial fibrillation, rash and nausea and vomiting) is uncertain. This study had 198 participants, but analysed only 175 of them for the thromboembolic outcomes (VTE, PE and DVT). </p> <p>One study with 100 participants compared heparin started 12 hours before surgery versus after surgery. Starting heparin before surgery may result in little or no difference in VTE or DVT. The effect on all‐cause and VTE‐related mortality was not estimable, as the study reported no events. Although the study authors reported no PE events, they did not use diagnostic methods to ascertain asymptomatic or oligosymptomatic PE. Therefore, we considered that this study did not offer enough data to assess the evidence on the effect of the intervention on PE risk. </p> <p>One study with 150 participants compared combined mechanical and pharmacological prophylaxis with mechanical prophylaxis alone in people undergoing bariatric surgery. Combined mechanical and pharmacological prophylaxis may reduce the risk of VTE and DVT. The effect on major bleeding, all‐cause mortality and VTE‐related mortality was not estimable, as the study reported no events in either group. Because the study authors did not attempt to ascertain asymptomatic or oligosymptomatic PE, we considered there were insufficient data to assess the effect of the intervention on PE. </p> <p>There were no data to assess the effect of these interventions on QoL.</p> </section> <section id="CD013683-sec-0116"> <h3 class="title" id="CD013683-sec-0116">Overall completeness and applicability of evidence</h3> <p>Obesity is considered a major risk factor for VTE, and all people with obesity who undergo surgery would usually have VTE prophylaxis in the absence of major contraindications (<a href="./references#CD013683-bbs2-0029" title="BartlettMA , MauckKF , DanielsPR . Prevention of venous thromboembolism in patients undergoing bariatric surgery. Vascular Health and Risk Management2015;11:461-77. [PMID: 26316771]">Bartlett 2015</a>). Although other pharmacological interventions are available in clinical practice, we found no studies using VKAs, DOACs or antiplatelet agents for preventing VTE in the bariatric surgery routine. In fact, it is unlikely that VKAs will ever be studied as a primary prophylactic intervention, as they are associated with higher risk of major bleeding and more complex anticoagulation control, as pointed out in the protocol of this review (<a href="./references#CD013683-bbs2-0097" title="AmaralFC , Baptista-SilvaJC , NakanoLC , FlumignanRL . Pharmacological interventions for preventing venous thromboembolism in patients undergoing bariatric surgery. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013683. [DOI: 10.1002/14651858.CD013683]">Amaral 2020</a>; <a href="./references#CD013683-bbs2-0091" title="StevensSM , WollerSC , KreuzigerLB , BounameauxH , DoerschugK , GeersingGJ , et al. Antithrombotic Therapy for VTE Disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):e545-608. [PMID: 10.1016/j.chest.2021.07.055]">Stevens 2021</a>; <a href="./references#CD013683-bbs2-0088" title="SmithM , WakamG , WakefieldT , ObiA . New trends in anticoagulation therapy. Surgical Clinics of North America2018;98(2):219-38. [PMID: 29502768]">Smith 2018</a>). However, studies addressing the effects of DOACs or antiplatelet agents would have been of great value to this review, as these drugs are used in the prophylaxis of thromboembolism in other situations (<a href="./references#CD013683-bbs2-0048" title="FlumignanCD , FlumignanRL , Baptista-SilvaJC . Antiplatelet agents for the treatment of deep venous thrombosis. Cochrane Database of Systematic Reviews2022, Issue 9. Art. No: CD012369. [DOI: 10.1002/14651858.CD012369.pub2]">Flumignan 2022b</a>; <a href="./references#CD013683-bbs2-0046" title="FlumignanRL , TinôcoJD , PascoalPI , AreiasLL , CossiMS , FernandesMI , et al. Prophylactic anticoagulants for people hospitalized with COVID-19: systematic review. British Journal of Surgery2021;108(9):e299-300. [DOI: 10.1093/bjs/znab197]">Flumignan 2021</a>; <a href="./references#CD013683-bbs2-0047" title="FlumignanRL , CivileVT , TinôcoJD , PascoalPI , AreiasLL , MatarCF , et al. Anticoagulants for people hospitalised with COVID-19. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD013739. [DOI: 10.1002/14651858.CD013739.pub2]">Flumignan 2022a</a>; <a href="./references#CD013683-bbs2-0083" title="SantosBC , FlumignanRL , CivileVT , AtallahAN , NakanoLC . Prophylactic anticoagulants for non-hospitalised people with COVID-19. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD015102. [DOI: 10.1002/14651858.CD015102]">Santos 2022</a>; <a href="./references#CD013683-bbs2-0091" title="StevensSM , WollerSC , KreuzigerLB , BounameauxH , DoerschugK , GeersingGJ , et al. Antithrombotic Therapy for VTE Disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):e545-608. [PMID: 10.1016/j.chest.2021.07.055]">Stevens 2021</a>). We did find two records of ongoing studies addressing the effect of DOACs in the prophylaxis of VTE in bariatric surgery patients (<a href="./references#CD013683-bbs2-0017" title="BalibreaJM , CorcellesR , MorenoP , MansE , SabenchF , VilallongaR , et al. Apixaban versus enoxaparin for postoperative thromboprophylaxis after sleeve gastrectomy. A proposal for randomized controlled trial. Obesity Surgery2017;27(1 Suppl 1):479-80. [DOI: 10.1007/s11695-017-2774-7]">Balibrea 2017</a>; <a href="./references#CD013683-bbs2-0020" title="NCT03522259. Rivaroxaban as thrombosis prophylaxis in bariatric surgery (BARIVA). clinicaltrials.gov/ct2/show/NCT03522259 (first received 30 April 2018). ">NCT03522259</a>), but at the time of writing there is no estimate of when data may be available. Because we only included studies that addressed the effects of heparins (UFH and LMWH) and pentasaccharides, the evidence in this review is valid only for these interventions. </p> <p>Although <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a> reported no DVT events, the participants only underwent duplex ultrasound at day 10 after surgery. Given that studies such as <a href="./references#CD013683-bbs2-0050" title="FroehlingDA , DanielsPR , MauckKF , Collazo-ClavellML , AshraniAA , SarrMG , et al. Incidence of venous thromboembolism after bariatric surgery: a population-based cohort study. Obesity Surgery2013;23(11):1874-9. [PMID: 24022324]">Froehling 2013</a> have reported a higher incidence of VTE within the first month of surgery, it is possible that <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a> underestimated the event occurrence. Nonetheless, <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a> and <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a> also reported no DVT event, although their participants had duplex ultrasound at least 30 days after surgery. The other included studies were effective in diagnosing and reporting DVT. Only one study reported PE. This may be because it is easier to diagnose asymptomatic DVT (as most cases were) than asymptomatic PE. As a result, the incidence of VTE and of DVT were almost the same. </p> <p>The included studies reported no deaths, which suggests a much larger sample is needed to address the effect of these interventions on mortality. No studies addressed QoL, and only three studies measured adverse events (<a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a>). </p> <p>Despite varying durations of follow‐up, the duration of the intervention itself was up to 15 days in all studies, with a minimum of seven days in <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>. Therefore, there is a lack of evidence assessing the duration of anticoagulation in people undergoing bariatric surgery. </p> <p>Because people undergoing bariatric surgery have increased weight, there is an argument for augmenting the heparin dose to reach an effective level, but because most trials have excluded people with severe obesity, there is little evidence to support this theory (<a href="./references#CD013683-bbs2-0091" title="StevensSM , WollerSC , KreuzigerLB , BounameauxH , DoerschugK , GeersingGJ , et al. Antithrombotic Therapy for VTE Disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):e545-608. [PMID: 10.1016/j.chest.2021.07.055]">Stevens 2021</a>). In addition, some people with higher BMI may have non‐alcoholic fatty liver disease, which affects their bleeding risk on anticoagulants (<a href="./references#CD013683-bbs2-0076" title="PillaiAA , RinellaME . Non-alcoholic fatty liver disease: is bariatric surgery the answer?Clinics in Liver Disease2009;13(4):689-710. [PMID: 19818313]">Pillai 2009</a>; <a href="./references#CD013683-bbs2-0091" title="StevensSM , WollerSC , KreuzigerLB , BounameauxH , DoerschugK , GeersingGJ , et al. Antithrombotic Therapy for VTE Disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):e545-608. [PMID: 10.1016/j.chest.2021.07.055]">Stevens 2021</a>). There are insufficient data in the included studies to support any difference in VTE prevalence according to BMI of participants, surgery type or surgery access (open surgery or laparoscopic). Most studies reported that the participants had also received mechanical interventions (e.g. early ambulation, compression stockings); however, <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a> provided no information in this regard. </p> </section> <section id="CD013683-sec-0117"> <h3 class="title" id="CD013683-sec-0117">Quality of the evidence</h3> <p>We found four RCTs with data for one comparison (higher‐dose heparin compared to standard‐dose heparin) and one RCT with data each for other comparisons (heparin compared to pentasaccharide, heparin starting before versus after the surgical procedure, and combined mechanical and pharmacological prophylaxis versus mechanical prophylaxis alone). </p> <p>The overall risk of bias was low for the fourth comparison, which included only <a href="./references#CD013683-bbs2-0002" title="AhmadKS , ZayedME , FaheemMH , EssaMS . Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. Surgical Innovation2021;28(1):144-50. [DOI: 10.1177/1553350620965812]TCTR20200127002. Incidence of silent DVT after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20200127002 (first received 27 January 2020). ">Ahmad 2021</a>. In the first two comparisons, we considered the risk of bias related to blinding of participants, random sequence generation or allocation concealment to be unclear or high for most studies (<a href="./references#CD013683-bbs2-0001" title="AbdelsalamAM , ElAnsaryAM , SalmanMA , NassefSA , ElferganyHM , AishaHA . Adding a preoperative dose of LMWH may decrease VTE following bariatric surgery. World Journal of Surgery2021;45(1):126-31. [PMID: 32989579]">Abdelsalam 2021</a>; <a href="./references#CD013683-bbs2-0003" title="EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Journal of Minimally Invasive Surgical Sciences2012;1(2):58-61. [DOI: 10.5812/jmiss.4991]EbrahimifardF , PazoukiA , Solaymani DodaranM , VaziriM . A comparison between two different prophylactic doses of unfractionated heparin for deep venous thrombosis prevention in laparoscopic bariatric surgery. Obesity Surgery2013;23(8):1167. [DOI: 10.1007/s11695-013-0986-z]IRCT201008253384N3. Effect of different doses of heparin in prophylaxis of deep vein thrombosis following laparoscopic bariatric surgery; a randomized clinical trial. en.irct.ir/trial/3459 (first received 5 October 2010). ">Ebrahimifard 2012</a>; <a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>). Risk of bias was high for selective reporting and other bias in the RCT included in the heparin versus pentasaccharide comparison, as 23 participants were lost from only one arm of the study (21 reported missing, two not reported missing but not included in the analysis), and the time point of outcome assessment in the published report differed from that prespecified in the protocol (<a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a>). See <a href="./references#CD013683-sec-0137" title="">Characteristics of included studies</a> for detailed information on the risk of bias assessment. </p> <p>The certainty of the evidence for all outcomes was low to very low. We downgraded the certainty of the evidence due to risk of bias, particularly with regard to performance and detection bias in three RCTs, and also reporting and other bias in one RCT. We downgraded the certainty of the evidence due to study limitations (risk of bias) and imprecision (few events, few participants and large CI) the first three comparisons. For the fourth comparison, we downgraded the certainty of the evidence for imprecision (small sample size and few events). See <a href="./full#CD013683-tbl-0001">summary of findings Table 1</a>, <a href="./full#CD013683-tbl-0002">summary of findings Table 2</a>, <a href="./full#CD013683-tbl-0003">summary of findings Table 3</a> and <a href="./full#CD013683-tbl-0004">summary of findings Table 4</a>. </p> </section> <section id="CD013683-sec-0118"> <h3 class="title" id="CD013683-sec-0118">Potential biases in the review process</h3> <p>With the aim of identifying all relevant randomised trials for this review, we performed a broad and sensitive search through the prespecified databases, with no limitations on language, date of publication or any other factor. Additionally, we searched through the references of the included studies, and through the references of other systematic reviews and guidelines (<a href="./references#CD013683-bbs2-0022" title="AbildgaardA , MadsenSA , HvasAM . Dosage of anticoagulants in obesity: recommendations based on a systematic review. Seminars in Thrombosis and Hemostasis2020;46(8):932-69. [PMID: 33368113]">Abildgaard 2020</a>; <a href="./references#CD013683-bbs2-0023" title="AgarwalR , HechtTE , LazoMC , UmscheidCA . Venous thromboembolism prophylaxis for patients undergoing bariatric surgery: a systematic review. Surgery for Obesity and Related Diseases2010;6(2):213-20. [PMID: 20176509]">Agarwal 2010</a>; <a href="./references#CD013683-bbs2-0029" title="BartlettMA , MauckKF , DanielsPR . Prevention of venous thromboembolism in patients undergoing bariatric surgery. Vascular Health and Risk Management2015;11:461-77. [PMID: 26316771]">Bartlett 2015</a>; <a href="./references#CD013683-bbs2-0030" title="BecattiniC , AgnelliG , ManinaG , NoyaG , RondelliF . Venous thromboembolism after laparoscopic bariatric surgery for morbid obesity: clinical burden and prevention. Surgery for Obesity and Related diseases2012;8(1):108-15. [PMID: 22014482]">Becattini 2012</a>; <a href="./references#CD013683-bbs2-0033" title="BrotmanDJ , ShihabHM , PrakasaKR , KebedeS , HautER , SharmaR , et al. Pharmacologic and mechanical strategies for preventing venous thromboembolism after bariatric surgery: a systematic review and meta-analysis. JAMA Surgery2013;148(7):675-86. [PMID: 23754086]">Brotman 2013</a>; <a href="./references#CD013683-bbs2-0060" title="IkesakaR , DellucA , Le GalG , CarrierM . Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis. Thrombosis Research2014;133(4):682-7. [DOI: 10.1016/j.thromres.2014.01.021]">Ikesaka 2014</a>; <a href="./references#CD013683-bbs2-0081" title="RochaAT , deVasconcellosAG , da Luz NetoER , AraújoDM , AlvesES , LopesAA . Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery. Obesity Surgery2006;16(12):1645-55. [PMID: 17217642]">Rocha 2006</a>; <a href="./references#CD013683-bbs2-0094" title="VenclauskasL , MaleckasA , ArcelusJI . European guidelines on perioperative venous thromboembolism prophylaxis: surgery in the obese patient. European Journal of Anaesthesiology2018;35(2):147-53. [PMID: 29112546]">Venclauskas 2018</a>). However, it is possible that we missed some trials, notably in the grey literature. We adhered to the eligibility criteria prespecified in the protocol to limit subjectivity (<a href="./references#CD013683-bbs2-0097" title="AmaralFC , Baptista-SilvaJC , NakanoLC , FlumignanRL . Pharmacological interventions for preventing venous thromboembolism in patients undergoing bariatric surgery. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013683. [DOI: 10.1002/14651858.CD013683]">Amaral 2020</a>). We tried to contact the study authors to obtain additional relevant data, but received no response in some cases. If additional data become available in the future, we will include them in future updates of this review. To reduce the potential bias of the review process, three review authors independently selected studies, extracted data and assessed risk of bias. Where possible, we performed additional analyses (subgroups and sensitivity analyses) as planned in our protocol, but our conclusions are based on our primary analysis (<a href="./references#CD013683-bbs2-0097" title="AmaralFC , Baptista-SilvaJC , NakanoLC , FlumignanRL . Pharmacological interventions for preventing venous thromboembolism in patients undergoing bariatric surgery. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013683. [DOI: 10.1002/14651858.CD013683]">Amaral 2020</a>). </p> </section> <section id="CD013683-sec-0119"> <h3 class="title" id="CD013683-sec-0119">Agreements and disagreements with other studies or reviews</h3> <p>There are other published systematic reviews on VTE prophylaxis for people undergoing bariatric surgery, but all have methodological differences compared with our review. </p> <p><a href="./references#CD013683-bbs2-0060" title="IkesakaR , DellucA , Le GalG , CarrierM . Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis. Thrombosis Research2014;133(4):682-7. [DOI: 10.1016/j.thromres.2014.01.021]">Ikesaka 2014</a> searched MEDLINE, Embase and Cochrane CENTRAL, and handsearched the references of the included studies and conference proceedings. <a href="./references#CD013683-bbs2-0060" title="IkesakaR , DellucA , Le GalG , CarrierM . Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis. Thrombosis Research2014;133(4):682-7. [DOI: 10.1016/j.thromres.2014.01.021]">Ikesaka 2014</a> considered all types of study design, included only studies reporting VTE or bleeding and imposed no restriction regarding language or year of publication. They reported the results of one of our included studies (<a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>). They used the RoB 1 tool to assess the risk of bias in the RCT, but used an obsolete risk of bias tool (the Modified Newcastle‐Ottawa Scoring System) for non‐randomised studies, and did not assess the certainty of evidence. Their search strategy included only pharmacological terms for heparin and did not consider DOACs or VKAs. <a href="./references#CD013683-bbs2-0060" title="IkesakaR , DellucA , Le GalG , CarrierM . Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis. Thrombosis Research2014;133(4):682-7. [DOI: 10.1016/j.thromres.2014.01.021]">Ikesaka 2014</a> combined six studies (one RCT, one quasi‐RCT and four NRS) in meta‐analyses and concluded that "adjusting the dose of heparin products for thromboprophylaxis post‐bariatric surgery seems to be associated with a lower rate of in hospital VTE compared to a strategy of not adjusting the dose, although this did not reach statistical significance". </p> <p><a href="./references#CD013683-bbs2-0030" title="BecattiniC , AgnelliG , ManinaG , NoyaG , RondelliF . Venous thromboembolism after laparoscopic bariatric surgery for morbid obesity: clinical burden and prevention. Surgery for Obesity and Related diseases2012;8(1):108-15. [PMID: 22014482]">Becattini 2012</a> searched MEDLINE and Embase, and handsearched the references of the included studies and other reviews, applying no language or publication date restrictions. <a href="./references#CD013683-bbs2-0030" title="BecattiniC , AgnelliG , ManinaG , NoyaG , RondelliF . Venous thromboembolism after laparoscopic bariatric surgery for morbid obesity: clinical burden and prevention. Surgery for Obesity and Related diseases2012;8(1):108-15. [PMID: 22014482]">Becattini 2012</a> aimed to include RCTs and observational studies, but retrieved no RCTs. They included only studies with videolaparoscopic surgery, reporting VTE and bleeding events. They did not use a standardised tool to assess the risk of bias of the included studies, and they did not describe any tool for assessing the certainty of the evidence. They included 19 observational studies, (12 prospective cohort studies and seven retrospective cohort studies). <a href="./references#CD013683-bbs2-0030" title="BecattiniC , AgnelliG , ManinaG , NoyaG , RondelliF . Venous thromboembolism after laparoscopic bariatric surgery for morbid obesity: clinical burden and prevention. Surgery for Obesity and Related diseases2012;8(1):108-15. [PMID: 22014482]">Becattini 2012</a> concluded that "the incidence of postoperative VTE seems to be relatively low in this setting, and the benefit of weight adjusted heparin prophylaxis remains controversial". </p> <p>In <a href="./references#CD013683-bbs2-0081" title="RochaAT , deVasconcellosAG , da Luz NetoER , AraújoDM , AlvesES , LopesAA . Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery. Obesity Surgery2006;16(12):1645-55. [PMID: 17217642]">Rocha 2006</a>, bariatric surgery patients were a subgroup of the target population. <a href="./references#CD013683-bbs2-0081" title="RochaAT , deVasconcellosAG , da Luz NetoER , AraújoDM , AlvesES , LopesAA . Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery. Obesity Surgery2006;16(12):1645-55. [PMID: 17217642]">Rocha 2006</a> searched MEDLINE, LILACS and the Cochrane CENTRAL databases, but did not mention any strategy for searching the grey literature. Their search strategy appears limited, as they only used a few Medical Subject Headings (MeSH) terms for obesity and VTE, without using free terms or correlated terms, and without searching for the pharmacological interventions. They considered all types of study design, and included only studies reporting VTE or bleeding. They imposed no language restrictions, but limited the search to studies published from 1976. They included six studies, but only one RCT, which is one of our included studies (<a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>). They did not mention any method for assessing risk of bias, but did assess the certainty of the evidence using the 2001 Oxford Centre for Evidence‐Based Medicine levels of evidence tool. Due to the limited number and quality of the included studies, <a href="./references#CD013683-bbs2-0081" title="RochaAT , deVasconcellosAG , da Luz NetoER , AraújoDM , AlvesES , LopesAA . Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery. Obesity Surgery2006;16(12):1645-55. [PMID: 17217642]">Rocha 2006</a> were unable to reach a conclusion regarding the more effective and safe prophylactic regimen. </p> <p><a href="./references#CD013683-bbs2-0023" title="AgarwalR , HechtTE , LazoMC , UmscheidCA . Venous thromboembolism prophylaxis for patients undergoing bariatric surgery: a systematic review. Surgery for Obesity and Related Diseases2010;6(2):213-20. [PMID: 20176509]">Agarwal 2010</a> performed an update to the <a href="./references#CD013683-bbs2-0081" title="RochaAT , deVasconcellosAG , da Luz NetoER , AraújoDM , AlvesES , LopesAA . Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery. Obesity Surgery2006;16(12):1645-55. [PMID: 17217642]">Rocha 2006</a> review. They searched for studies from 2006 to 2009 in MEDLINE and Cochrane CENTRAL (without LILACS), and included the studies already retrieved in the <a href="./references#CD013683-bbs2-0081" title="RochaAT , deVasconcellosAG , da Luz NetoER , AraújoDM , AlvesES , LopesAA . Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery. Obesity Surgery2006;16(12):1645-55. [PMID: 17217642]">Rocha 2006</a> search, as well as studies from the reference lists of other reviews and guidelines. They considered all types of study design and included only studies published in English that reported VTE or bleeding and mortality. They analysed 30 studies, but only one RCT (<a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>), which is also in our review. The remaining 29 studies were non‐RCTs (N = 7) or uncontrolled studies (N = 22). They did not mention any tool for assessing risk of bias or certainty of the evidence. <a href="./references#CD013683-bbs2-0023" title="AgarwalR , HechtTE , LazoMC , UmscheidCA . Venous thromboembolism prophylaxis for patients undergoing bariatric surgery: a systematic review. Surgery for Obesity and Related Diseases2010;6(2):213-20. [PMID: 20176509]">Agarwal 2010</a> concluded that "although patients undergoing bariatric surgery are at a major risk of VTE, the various thromboprophylactic agents have been poorly studied in this setting". </p> <p><a href="./references#CD013683-bbs2-0029" title="BartlettMA , MauckKF , DanielsPR . Prevention of venous thromboembolism in patients undergoing bariatric surgery. Vascular Health and Risk Management2015;11:461-77. [PMID: 26316771]">Bartlett 2015</a> searched MEDLINE, Embase, Cochrane CENTRAL and ClinicalTrials.gov, and handsearched the references of the included studies and other reviews, limiting the search to studies published in English. They considered RCTs and cohort studies that compared two or more groups and that reported VTE or bleeding and mortality. Their search strategy did not include terms describing the interventions. The review included 14 studies, with two RCTs (<a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>), both of which are in our review. <a href="./references#CD013683-bbs2-0029" title="BartlettMA , MauckKF , DanielsPR . Prevention of venous thromboembolism in patients undergoing bariatric surgery. Vascular Health and Risk Management2015;11:461-77. [PMID: 26316771]">Bartlett 2015</a> did not mention how they assessed risk of bias or certainty of the evidence. <a href="./references#CD013683-bbs2-0029" title="BartlettMA , MauckKF , DanielsPR . Prevention of venous thromboembolism in patients undergoing bariatric surgery. Vascular Health and Risk Management2015;11:461-77. [PMID: 26316771]">Bartlett 2015</a> concluded that "until more data are available, institutional quality improvement efforts should focus on ensuring consistent application of established methods". </p> <p><a href="./references#CD013683-bbs2-0033" title="BrotmanDJ , ShihabHM , PrakasaKR , KebedeS , HautER , SharmaR , et al. Pharmacologic and mechanical strategies for preventing venous thromboembolism after bariatric surgery: a systematic review and meta-analysis. JAMA Surgery2013;148(7):675-86. [PMID: 23754086]">Brotman 2013</a> searched MEDLINE, Embase, Scopus, CINAHL, International Pharmaceutical Abstracts, ClinicalTrials.gov and the Cochrane Library, and handsearched the references of the included studies and other reviews. They included 13 observational cohort studies. The outcomes of interest were VTE, bleeding events, all‐cause mortality and adverse drug reactions. <a href="./references#CD013683-bbs2-0033" title="BrotmanDJ , ShihabHM , PrakasaKR , KebedeS , HautER , SharmaR , et al. Pharmacologic and mechanical strategies for preventing venous thromboembolism after bariatric surgery: a systematic review and meta-analysis. JAMA Surgery2013;148(7):675-86. [PMID: 23754086]">Brotman 2013</a> assessed risk of bias with "10 items from the Downs and Black instrument" and the certainty of the evidence "by adapting a grading scheme recommended in the Methods Guide for Effectiveness and Comparative Effectiveness Reviews". <a href="./references#CD013683-bbs2-0033" title="BrotmanDJ , ShihabHM , PrakasaKR , KebedeS , HautER , SharmaR , et al. Pharmacologic and mechanical strategies for preventing venous thromboembolism after bariatric surgery: a systematic review and meta-analysis. JAMA Surgery2013;148(7):675-86. [PMID: 23754086]">Brotman 2013</a> did not find evidence to support the use of a higher dose of pharmacotherapy in people undergoing bariatric surgery. </p> <p><a href="./references#CD013683-bbs2-0059" title="HussainZ , CurtainC , MirkazemiC , ZaidiST . Peri-operative medication dosing in adult obese elective surgical patients: a systematic review of clinical studies. Clinical Drug Investigation2018;38(8):673-93. [PMID: 29855999]">Hussain 2018</a> is a systematic review of a variety of drugs in people with obesity; anticoagulants in bariatric surgery patients is a subgroup. <a href="./references#CD013683-bbs2-0059" title="HussainZ , CurtainC , MirkazemiC , ZaidiST . Peri-operative medication dosing in adult obese elective surgical patients: a systematic review of clinical studies. Clinical Drug Investigation2018;38(8):673-93. [PMID: 29855999]">Hussain 2018</a> searched MEDLINE, Embase, CINAHL and Cochrane databases with a comprehensive search strategy. They considered all types of study design, included only studies reporting VTE or bleeding and imposed no restrictions regarding language or year of publication. They identified seven studies that analysed the effect of anticoagulant prophylaxis in bariatric surgery patients, including three RCTs (<a href="./references#CD013683-bbs2-0004" title="ImbertiD , BaldiniE , PierfranceschiMG , NicoliniA , CartelliC , De PaoliM , et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery2014;24(2):284-91. [DOI: 10.1007/s11695-013-1105-x]ImbertiD , LegnaniC , BaldiniE , CiniM , NicoliniA , GuerraM , et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research2009;124(6):667-71. [DOI: 10.1016/j.thromres.2009.04.021]">Imberti 2014b</a>; <a href="./references#CD013683-bbs2-0005" title="KalfarentzosF , StavropoulouF , YarmenitisS , KehagiasI , KaramesiniM , DimitrakopoulosA , et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obesity Surgery2001;11(6):670-6. [DOI: 10.1381/09608920160558588]">Kalfarentzos 2001</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>), all of which are also in our review. <a href="./references#CD013683-bbs2-0059" title="HussainZ , CurtainC , MirkazemiC , ZaidiST . Peri-operative medication dosing in adult obese elective surgical patients: a systematic review of clinical studies. Clinical Drug Investigation2018;38(8):673-93. [PMID: 29855999]">Hussain 2018</a> assessed risk of bias using the Meta‐Analysis of Statistics Assessment and Review Instrument (MAStARI) for the cohort (with control) and randomised studies, and assessed the certainty of the evidence using the National Health and Medical Research Council GRADE tool. <a href="./references#CD013683-bbs2-0059" title="HussainZ , CurtainC , MirkazemiC , ZaidiST . Peri-operative medication dosing in adult obese elective surgical patients: a systematic review of clinical studies. Clinical Drug Investigation2018;38(8):673-93. [PMID: 29855999]">Hussain 2018</a> concluded that "optimal dose adjustment for obese patients remained unclear". </p> <p><a href="./references#CD013683-bbs2-0022" title="AbildgaardA , MadsenSA , HvasAM . Dosage of anticoagulants in obesity: recommendations based on a systematic review. Seminars in Thrombosis and Hemostasis2020;46(8):932-69. [PMID: 33368113]">Abildgaard 2020</a> is a systematic review on the prophylactic use of anticoagulants in obese clinical and surgical patients. Bariatric surgery patients constituted a subgroup of participants. <a href="./references#CD013683-bbs2-0022" title="AbildgaardA , MadsenSA , HvasAM . Dosage of anticoagulants in obesity: recommendations based on a systematic review. Seminars in Thrombosis and Hemostasis2020;46(8):932-69. [PMID: 33368113]">Abildgaard 2020</a> searched MEDLINE and Embase, restricting the search to English‐language publications but applying no publication date limitation. They included RCTs and observational studies that reported clinical efficacy or biochemical efficacy (antifactor Xa levels) and bleeding. They identified 22 studies that addressed the same subject as this review, including two RCTs (<a href="./references#CD013683-bbs2-0006" title="NCT00894283. Comparing enoxaparin to fondaparinux to prevent venous thromboembolism (VTE) in bariatric surgical patients. clinicaltrials.gov/ct2/show/NCT00894283 (first received 5 May 2009). SteeleKE , CannerJ , ProkopowiczG , VerdeF , BeselmanA , WyseR , et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surgery for Obesity and Related Diseases2015;11(3):672-83. [DOI: 10.1016/j.soard.2014.10.003]SteeleKE , SchweitzerMA . Prevalence of asymptomatic deep venous thrombosis among bariatric surgical patients receiving perioperative enoxaparin versus fondaparinux. Clinical and Translational Science2013;6(2):117. ">Steele 2015b</a>; <a href="./references#CD013683-bbs2-0007" title="NCT00444652. Thromboprophylaxis and bariatric surgery. clinicaltrials.gov/ct2/show/NCT00444652 (first received 8 March 2007). SteibA , DegirmenciSE , JunkeE , AsehnouneK , FigierM , PericardC , et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases2016;12(3):613-21. [DOI: 10.1016/j.soard.2015.08.505]">Steib 2016</a>), both of which are also in our review. <a href="./references#CD013683-bbs2-0022" title="AbildgaardA , MadsenSA , HvasAM . Dosage of anticoagulants in obesity: recommendations based on a systematic review. Seminars in Thrombosis and Hemostasis2020;46(8):932-69. [PMID: 33368113]">Abildgaard 2020</a> concluded with some dosage recommendations, but did not describe any assessment of the certainty of the evidence or risk of bias. </p> <p>Given the cited limitations of these reviews, our review appears to be more comprehensive, including more RCTs and more comparisons. However, due to the lack of high‐quality studies, the evidence remains of low or very low certainty. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013683-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013683-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full#CD013683-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013683-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full#CD013683-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013683-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full#CD013683-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Higher‐dose heparin versus standard‐dose heparin, Outcome 1: Venous thromboembolism" data-id="CD013683-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Higher‐dose heparin versus standard‐dose heparin, Outcome 1: Venous thromboembolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Higher‐dose heparin versus standard‐dose heparin, Outcome 2: Major bleeding" data-id="CD013683-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Higher‐dose heparin versus standard‐dose heparin, Outcome 2: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Higher‐dose heparin versus standard‐dose heparin, Outcome 3: All‐cause mortality" data-id="CD013683-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Higher‐dose heparin versus standard‐dose heparin, Outcome 3: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Higher‐dose heparin versus standard‐dose heparin, Outcome 4: Venous thromboembolism‐related mortality" data-id="CD013683-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Higher‐dose heparin versus standard‐dose heparin, Outcome 4: Venous thromboembolism‐related mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Higher‐dose heparin versus standard‐dose heparin, Outcome 5: Pulmonary embolism" data-id="CD013683-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Higher‐dose heparin versus standard‐dose heparin, Outcome 5: Pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Higher‐dose heparin versus standard‐dose heparin, Outcome 6: Deep vein thrombosis" data-id="CD013683-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Higher‐dose heparin versus standard‐dose heparin, Outcome 6: Deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Higher‐dose heparin versus standard‐dose heparin, Outcome 7: Adverse events (thrombocytopaenia)" data-id="CD013683-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Higher‐dose heparin versus standard‐dose heparin, Outcome 7: Adverse events (thrombocytopaenia) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Heparin versus pentasaccharide, Outcome 1: Venous thromboembolism" data-id="CD013683-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Heparin versus pentasaccharide, Outcome 1: Venous thromboembolism</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Heparin versus pentasaccharide, Outcome 2: Major bleeding" data-id="CD013683-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Heparin versus pentasaccharide, Outcome 2: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Heparin versus pentasaccharide, Outcome 3: All‐cause mortality" data-id="CD013683-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Heparin versus pentasaccharide, Outcome 3: All‐cause mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Heparin versus pentasaccharide, Outcome 4: Venous thromboembolism‐related mortality" data-id="CD013683-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Heparin versus pentasaccharide, Outcome 4: Venous thromboembolism‐related mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Heparin versus pentasaccharide, Outcome 5: Pulmonary embolism" data-id="CD013683-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Heparin versus pentasaccharide, Outcome 5: Pulmonary embolism</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Heparin versus pentasaccharide, Outcome 6: Deep vein thrombosis" data-id="CD013683-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Heparin versus pentasaccharide, Outcome 6: Deep vein thrombosis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Heparin versus pentasaccharide, Outcome 7: Adverse events (thrombocytopaenia)" data-id="CD013683-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Heparin versus pentasaccharide, Outcome 7: Adverse events (thrombocytopaenia)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Heparin versus pentasaccharide, Outcome 8: Adverse events (atrial fibrillation)" data-id="CD013683-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Heparin versus pentasaccharide, Outcome 8: Adverse events (atrial fibrillation)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Heparin versus pentasaccharide, Outcome 9: Adverse events (rash)" data-id="CD013683-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Heparin versus pentasaccharide, Outcome 9: Adverse events (rash)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Heparin versus pentasaccharide, Outcome 10: Adverse events (nausea and vomiting)" data-id="CD013683-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Heparin versus pentasaccharide, Outcome 10: Adverse events (nausea and vomiting) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Heparin started before versus after the surgical procedure, Outcome 1: Venous thromboembolism" data-id="CD013683-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Heparin started before versus after the surgical procedure, Outcome 1: Venous thromboembolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Heparin started before versus after the surgical procedure, Outcome 2: Major bleeding" data-id="CD013683-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Heparin started before versus after the surgical procedure, Outcome 2: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Heparin started before versus after the surgical procedure, Outcome 3: All‐cause mortality" data-id="CD013683-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Heparin started before versus after the surgical procedure, Outcome 3: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Heparin started before versus after the surgical procedure, Outcome 4: Venous thromboembolism‐related mortality" data-id="CD013683-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Heparin started before versus after the surgical procedure, Outcome 4: Venous thromboembolism‐related mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Heparin started before versus after the surgical procedure, Outcome 5: Deep vein thrombosis" data-id="CD013683-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Heparin started before versus after the surgical procedure, Outcome 5: Deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Combined mechanical and pharmacological prophylaxis versus mechanical prophylaxis alone, Outcome 1: Venous thromboembolism" data-id="CD013683-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Combined mechanical and pharmacological prophylaxis versus mechanical prophylaxis alone, Outcome 1: Venous thromboembolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Combined mechanical and pharmacological prophylaxis versus mechanical prophylaxis alone, Outcome 2: Major bleeding" data-id="CD013683-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Combined mechanical and pharmacological prophylaxis versus mechanical prophylaxis alone, Outcome 2: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Combined mechanical and pharmacological prophylaxis versus mechanical prophylaxis alone, Outcome 3: All‐cause mortality" data-id="CD013683-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Combined mechanical and pharmacological prophylaxis versus mechanical prophylaxis alone, Outcome 3: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Combined mechanical and pharmacological prophylaxis versus mechanical prophylaxis alone, Outcome 4: Venous thromboembolism‐related mortality" data-id="CD013683-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Combined mechanical and pharmacological prophylaxis versus mechanical prophylaxis alone, Outcome 4: Venous thromboembolism‐related mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013683-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/urn:x-wiley:14651858:media:CD013683:CD013683-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Combined mechanical and pharmacological prophylaxis versus mechanical prophylaxis alone, Outcome 5: Deep vein thrombosis" data-id="CD013683-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_t/tCD013683-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Combined mechanical and pharmacological prophylaxis versus mechanical prophylaxis alone, Outcome 5: Deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/media/CDSR/CD013683/image_n/nCD013683-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013683-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Higher‐dose heparin compared to standard‐dose heparin for preventing venous thromboembolism in people undergoing bariatric surgery</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Higher‐dose heparin compared to standard‐dose heparin for preventing venous thromboembolism in people undergoing bariatric surgery</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people undergoing bariatric surgery<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> higher‐dose heparin<br/><b>Comparison:</b> standard‐dose heparin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard‐dose heparin</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with higher‐dose heparin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>VTE</b><br/>Follow‐up: 10–90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>597<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.55</b><br/>(0.05 to 5.99) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(0 to 43) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b><br/>Follow‐up: 10–90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>597<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.19</b><br/>(0.48 to 2.96) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 per 1000<br/>(19 to 118) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: 10–90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>597<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>4 studies reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VTE‐related mortality</b><br/>Follow‐up: 10–90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>597<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>4 studies reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>PE</b><br/>Follow‐up: up to 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>310<br/>(2 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.37</b><br/>(0.02 to 8.92) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(0 to 55) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DVT</b><br/>Follow‐up: 10–90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>597<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.10</b><br/>(0.07 to 17.40) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(0 to 63) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events (thrombocytopenia)</b><br/>Follow‐up: up to 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>310<br/>(2 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.10</b><br/>(0.07 to 17.40) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/>(0 to 108) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>DVT:</b> deep vein thrombosis; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to high risk of performance and detection bias.<br/><sup>b</sup>Downgraded one level due to imprecision: few events and 95% CI consistent with possible benefit and possible harm.<br/><sup>c</sup>Downgraded two levels due to imprecision: no events.<br/><sup>d</sup>Downgraded two levels due to imprecision: very large CI of the absolute difference and few events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Higher‐dose heparin compared to standard‐dose heparin for preventing venous thromboembolism in people undergoing bariatric surgery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full#CD013683-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013683-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Heparin compared to pentasaccharide for preventing venous thromboembolism in people undergoing bariatric surgery</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Heparin compared to pentasaccharide for preventing venous thromboembolism in people undergoing bariatric surgery</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people undergoing bariatric surgery<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> heparin<br/><b>Comparison:</b> pentasaccharide </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with pentasaccharide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with heparin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>VTE</b><br/>Follow‐up: up to 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>175<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.83</b><br/>(0.19 to 3.61) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/>(8 to 157) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b><br/>Follow‐up: up to 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>198<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.70</b><br/>(0.42 to 6.92) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 per 1000<br/>(13 to 208) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: up to 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>198<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1 study reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VTE‐related mortality</b><br/>Follow‐up: up to 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>198<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1 study reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PE</b><br/>Follow‐up: up to 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>198<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1 study reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DVT</b><br/>Follow‐up: up to 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>175<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.83</b><br/>(0.19 to 3.61) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/>(8 to 157) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events (thrombocytopenia)</b><br/>Follow‐up: up to 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>198<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.34</b><br/>(0.01 to 8.25) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> <p>(0 to 83)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>DVT:</b> deep vein thrombosis; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to high risk of reporting and other bias.<br/><sup>b</sup>Downgraded one level due to imprecision: few participants, and 95% CI consistent with possible benefit and possible harm.<br/><sup>c</sup>Downgraded two levels due to imprecision: very large CI of the absolute difference and few events.<br/><sup>d</sup>Downgraded two levels due to imprecision: no events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Heparin compared to pentasaccharide for preventing venous thromboembolism in people undergoing bariatric surgery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full#CD013683-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013683-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Heparin started before compared to after the surgical procedure for preventing venous thromboembolism in people undergoing bariatric surgery</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Heparin started before versus after the surgical procedure for preventing venous thromboembolism in people undergoing bariatric surgery</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people undergoing bariatric surgery<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> heparin started 12 hours before surgery<br/><b>Comparison:</b> heparin started after surgery </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with heparin after surgery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with heparin 12 h before surgery</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>VTE</b><br/>Follow‐up: 15 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.11</b><br/>(0.01 to 2.01) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 per 1000 (1 to 161)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b><br/>Follow‐up: 15 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.00</b><br/>(0.13 to 71.92) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: 15 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1 study reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VTE‐related mortality</b><br/>Follow‐up: 15 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1 study reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PE</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DVT</b><br/>Follow‐up: 15 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.11</b><br/>(0.01 to 2.01) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 per 1000 (1 to 161)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (thrombocytopenia)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>DVT:</b> deep vein thrombosis; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to high risk of performance bias.<br/><sup>b</sup>Downgraded one level due to imprecision: few participants, and 95% CI consistent with possible benefit and possible harm.<br/><sup>c</sup>Downgraded two levels due to imprecision: no events.<br/><sup>d</sup>Downgraded two levels due to imprecision: very large CI of the absolute difference and few events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Heparin started before compared to after the surgical procedure for preventing venous thromboembolism in people undergoing bariatric surgery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full#CD013683-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013683-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Combined mechanical and pharmacological prophylaxis compared to mechanical prophylaxis alone for preventing venous thromboembolism in people undergoing bariatric surgery</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Combined mechanical and pharmacological prophylaxis compared to mechanical prophylaxis alone for preventing venous thromboembolism in people undergoing bariatric surgery</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people undergoing bariatric surgery<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> combined mechanical and pharmacological prophylaxis<br/><b>Comparison:</b> mechanical prophylaxis alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with mechanical prophylaxis alone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with combined mechanical and pharmacological prophylaxis</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>VTE</b><br/>Follow‐up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.05</b><br/>(0.00 to 0.89) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/>(0 to 107) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major bleeding</b><br/>Follow‐up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1 study reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1 study reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VTE‐related mortality</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1 study reported no events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PE</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>DVT</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.05</b><br/>(0.00 to 0.89) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/>(0 to 107) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>DVT:</b> deep vein thrombosis; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Number needed to treat for an additional beneficial outcome (NNTB) = 9.<br/><sup>b</sup>Downgraded two levels due to imprecision: few participants and few or no events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Combined mechanical and pharmacological prophylaxis compared to mechanical prophylaxis alone for preventing venous thromboembolism in people undergoing bariatric surgery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full#CD013683-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013683-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of terms</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Term</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjustable gastric banding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgical treatment for obesity where a silicone belt or band is placed around the upper portion of the stomach, shaping the stomach in an 'hourglass' form and restricting the flow of food </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticoagulants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drugs that suppress, delay or prevent blood clots</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antiplatelet agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drugs that prevent blood clots by inhibiting platelet function</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Atherosclerosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A disease characterised by a build‐up of abnormal fat, cholesterol and platelet deposits on the inner wall of the arteries </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biliopancreatic diversion with duodenal switch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgical treatment for obesity that involves reducing the size of the stomach by removing some of it, then bypassing most of the intestine </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body mass index (BMI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body mass divided by the square of the body height, universally expressed in units of kg/m<sup>2</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bariatric surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any type of surgery aimed at weight loss</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deep vein thrombosis (DVT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coagulation or clotting of the blood in a deep vein (i.e. far beneath the surface of the skin) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duplex ultrasound</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐invasive evaluation of blood flow through the arteries and veins by ultrasound devices </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dyslipidaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abnormal concentration of fats (lipids or lipoproteins) in the blood</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastric imbrication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Also known as stomach folding; surgical procedure to reduce the stomach volume without resection </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A drug used to prevent blood clotting (anticoagulant, blood thinner)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laparoscopic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A procedure performed via an endoscope inserted through an incision in the abdominal wall and used for viewing or performing minor surgery in the abdominal or pelvic cavities </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐molecular‐weight heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A drug used to prevent blood clotting (anticoagulant)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Obesity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Where the amount of body fat is beyond healthy conditions (BMI greater than 30 kg/m<sup>2</sup>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excess watery fluid that collects in tissues of the body, causing swelling when fluid leaks out of the body's vessels </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overweight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Where the amount of body fat is over that of the average population, but less than unhealthy conditions (BMI between 25 kg/m<sup>2</sup> and 30 kg/m<sup>2</sup>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Substance or treatment with no active effect, like a sugar pill</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary embolism (PE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood clot in the lung or blood vessel leading to the lung. The clot originates in a vein (e.g. DVT) and travels to the lung. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised clinical trial (RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A study in which the participants are divided randomly into separate groups to compare different treatments </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roux‐en‐Y gastric bypass</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgical treatment for obesity where the surgeon creates a small pouch at the top of the stomach, limiting the amount of food that can be eaten. The small intestine is also cut and connected to the new pouch. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Superficial thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inflammatory thrombotic disorder in which a clot develops in a vein near the surface of the skin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleeve gastrectomy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bariatric surgery in which most of the stomach is removed, leaving a small sleeve</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local coagulation of blood (clot) in a part of the circulatory system</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unfractionated heparin (UFH)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A mixture of heparins obtained from animals that is used to prevent blood coagulation, to prevent and treat clotting disorders </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vascular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relating to blood vessels (arteries and veins)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vena cava</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The largest human vein that returns blood to the heart after it has passed around the body </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relating to a vein</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venous thromboembolism (VTE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A condition that involves a blood clot forming in a vein, and sometimes migrating to another location (e.g. the lung) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Virchow's Triad</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 factors that contribute to thrombosis:</p> <p> <ul id="CD013683-list-0001"> <li> <p>changes in the vessel wall;</p> </li> <li> <p>changes in the pattern of blood flow; and</p> </li> <li> <p>changes in the blood constituents (hypercoagulability).</p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of terms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full#CD013683-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013683-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Classification of adults according to BMI</span></div> <tbody> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Classification</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>BMI values<sup>a</sup> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Underweight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 18.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Normal range</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5–24.99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Overweight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Preobese</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.00–29.99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Obese class I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.00–34.99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Obese class II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.00–39.99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Obese class Ill</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 40</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>BMI: body mass index.</p> <p><sup>a</sup>Body mass divided by the square of the body height, universally expressed in units of kg/m<sup>2</sup>.These BMI values are age‐ and sex‐independent. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Classification of adults according to BMI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/full#CD013683-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013683-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Higher‐dose heparin versus standard‐dose heparin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.05, 5.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.48, 2.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.04, 5.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Low molecular weight heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.48, 5.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Low molecular weight heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Venous thromboembolism‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Low molecular weight heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.02, 8.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.07, 17.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Low molecular weight heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.07, 17.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Adverse events (thrombocytopaenia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.07, 17.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Higher‐dose heparin versus standard‐dose heparin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013683-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Heparin versus pentasaccharide</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.19, 3.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.42, 6.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Venous thromboembolism‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.19, 3.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Adverse events (thrombocytopaenia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Adverse events (atrial fibrillation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.19, 22.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Adverse events (rash) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.06, 16.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Adverse events (nausea and vomiting) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.15, 7.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Heparin versus pentasaccharide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013683-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Heparin started before versus after the surgical procedure</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 71.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Venous thromboembolism‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Heparin started before versus after the surgical procedure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013683-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Combined mechanical and pharmacological prophylaxis versus mechanical prophylaxis alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.00, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Venous thromboembolism‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.00, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Combined mechanical and pharmacological prophylaxis versus mechanical prophylaxis alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013683.pub2/references#CD013683-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013683.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013683-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013683-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013683-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013683-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD013683-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013683-note-0015">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD013683-note-0010">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013683-note-0008">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013683-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013683\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013683\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013683\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013683\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013683\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013683\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013683\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013683\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013683\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013683\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013683\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013683\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013683\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013683\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013683\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013683\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013683\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013683\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tlnpj831&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013683.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013683.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013683.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013683.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013683.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726969589"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013683.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726969592"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013683.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ea09f6b97f401',t:'MTc0MDcyNjk2OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 